35272&2/6+3
7,7/( $3KDVH2SHQ ODEHO6WXG\WR(YDOXDWHWKH3KDUPDFRNLQHWLFV6 DIHW\
DQG7ROHUDELOLW\DQG3KDUPDFRG\QDPLFVRID6LQJOH'RVHRI/DQDGHOXPDE$GPLQLVWHUHG6XEFXWDQHRXVO\LQ+HDOWK\$GXOW-DSDQH VH
6XEMHFWVDQG0DWFKHG+HDOWK\$GXOW&DXFDVLDQ6XEMHFWV
'58* 6+3ODQDGHOXPDEIRUPHU O\';
,1' 
(8'5$&712
1RQ(8'5$&7
6321625 '\D[&RUSDQLQGLUHFWDQGZKROO\RZQHGVXEVLGLDU\RI6KLUHSO F
6KLUH:D\/H[LQJWRQ0$ 86$
35,1&,3$/
&225',1$7,1*,19(67,*$7250'
:HVW&RDVW&OLQLFDO7ULDOV:HVW&HUULWRV$YHQXH&\SUHVV&$ 86$
35272&2/
+,6725<2ULJLQDO3URWRFRO1RY
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLDODQGSURSULHWDU\LQIRUPDWLRQ RI6KLUHDQGLVGLVFORVHGSXUVXDQWWR
FRQILGHQWLDOLW\DQGQRQGLVFORVXUHREOLJDWLRQV7KLVLQIRUPDWLR QVKRXOGEHXVHGVROHO\IRUWKHSXUSRVHVIRUZKLFK
LWZDVSURYLGHGDQGVKRXOGQRWEHFRSLHGVKDUHGZLWKRUGLVFO RVHGWRDQ\WKLUGSDUW\ZLWKRXWWKHH[SUHVVZULWWHQ
FRQVHQWRI6KLUH
PPD
6KLUH &21),'(17,$/ 3DJH
3URWRFRO6+3
/DQDGHOXPDE 1RY
352'8&748$/,7<&203/$,176
,QYHVWLJDWRUVDUHUHTXLUHGWRUHSRUWLQYHVWLJDWLRQDOSURGXFWTX DOLW\FRPSODLQWVWR6KLUHZLWKLQ
KRXUV7KLVLQFOXGHVDQ\LQVWDQFHVZKHUHLQWKHTXDOLW\RUSHU IRUPDQFHRID6KLUHSURGXFW
PDUNHWHGRULQYHVWLJDWLRQDOGRHVQRWPHHWH[SHFWDWLRQVHJL QDGHTXDWHRUIDXOW\FORVXUH
SURGXFWFRQWDPLQDWLRQRUWKDWWKHSURGXFWGLGQRWPHHWWKHVSH FLILFDWLRQVGHILQHGLQWKH
DSSOLFDWLRQIRUWKHSURGXFWHJZURQJSURGXFWVXFKWKDWWKHOD EHODQGFRQWHQWVDUHGLIIHUHQW
SURGXFWV)RULQVWUXFWLRQVRQUHSRUWLQJ$(VUHODWHGWRSURGXFW FRPSODLQWVVHH6HFWLRQ 
3OHDVHXVHWKHLQIRUPDWLRQEHORZDVDSSOLFDEOHWRUHSRUWWKH3U RGXFW4XDOLW\&RPSODLQW
2ULJLQRI3URGXFW4XDOLW\&RPSODLQW (PDLO$GGUHVV
1RUWKDQG6RXWK$PHULFD
(XURSHDQ8QLRQDQG5HVWRI:RUOG
7HOHSKRQHQXPEHUVSURYLGHGIRUUHIHUHQFHLIQHHGHG
6KLUH/H[LQJWRQ0$86$PPD
PPD
PPD
Shire CONFIDENTIAL Page 6
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
TABLE OF CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
EMERGENCY CONTACT I NFORMATION ................................................................................3
ADDITIONAL CON TACT I NFORMATION ................................................................................4
PRODUCT QUALITY COMP LAINTS ..........................................................................................5
LIST OF TABLES .........................................................................................................................10
LIST OF FIGURES .......................................................................................................................10
ABBREVIAT IONS .......................................................................................................................11
STUDY SYNOPSI S
......................................................................................................................13
STUDY SCHEDULE(S) ...............................................................................................................19
1BACKGROUND INFORMAT ION
.......................................................................................22
1.1 Indication and Current Treatment Options ...............................................................22
1.2 Product Background .................................................................................................23
1.2.1 Preclinical Informa tion..........................................................................................23
1.2.2 Clinical I nformation ...............................................................................................23
1.3 Risk/Benefit and Ethical Assessment .......................................................................23
2STUDY OBJECTIVES AND PURPOSE ..............................................................................23
2.1 Rationale for the Study .............................................................................................23
2.2 Study  Objectives ......................................................................................................24
2.2.1 Primary  Objectives .................................................................................................24
2.2.2 Secondary  Objectives .............................................................................................24
2.2.3 Exploratory  Objectives ..........................................................................................24
3STUDY DESIGN ...................................................................................................................25
3.1 Study  Design and Flow Chart ..................................................................................25
3.2 Duration and Study  Completion Definition .............................................................26
3.3 Sites and Regions .....................................................................................................26
4STUDY POPUL ATION................................ ................................ ................................ ......... 26
4.1 Inclusion Criteria................................ ................................ ................................ ......26
4.2 Exclusion Criteria .....................................................................................................27
4.3 Restrictions ................................ ................................ ................................ ............... 28
4.4 Reproductive Potential ................................ ................................ ............................. 29
4.4.1 Female Contraception ............................................................................................29
4.4.2 Male Contraception ................................................................................................29
4.5
Discontinuation of Subjects ................................ ................................ ..................... 30
4.5.1 Reasons for Discontinuation ................................ ................................ .................. 30
4.5.2 Subjects ‚ÄúL ost to Follow -up‚Äù Prior to Last Sch eduled Visit ................................ .30
Shire CONFIDENTIAL Page 7
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
5PRIOR AND CONCOMITAN T TREATMENT ...................................................................31
5.1 Prior Treatment ........................................................................................................31
5.2 Concomitant Treatment ............................................................................................31
5.2.1 Permitted Treatment ...............................................................................................31
6INVESTIGAT IONAL PROD UCT ........................................................................................31
6.1 Identity  of Investigational Product ...........................................................................31
6.1.1 Blinding the Treatment Assignment ......................................................................31
6.2 Administration of I nvestigational Product ...............................................................31
6.2.1 Allocation of Subjects to Treatment ......................................................................31
6.2.2 Dosing ....................................................................................................................32
6.2.3 Unblinding the Treatment Assignment ..................................................................32
6.3 Labeling, Packag ing, Storage, and Handling ...........................................................32
6.3.1 Labeling .................................................................................................................32
6.3.2 Packaging ...............................................................................................................33
6.3.3 Storage ...................................................................................................................33
6.4 Drug Accountability .................................................................................................33
6.5 Subject Compliance ..................................................................................................34
6.6 Retention of Bioavailability  and Bioequivalence Testing Samples .........................34
7
STUDY PROCEDURES........................................................................................................35
7.1 Study  Schedule .........................................................................................................35
7.1.1 Screening Period ....................................................................................................35
7.1.1.1 Screening Failure ....................................................................................35
7.1.1.2 Rescreening of Subjects .........................................................................35
7.1.2 Treatment Period ....................................................................................................36
7.1.2.1 In-house Confinement Period (Day 1 to Day  5)................................ ....36
7.1.2.2 Out-Patient Visit Period (Day  6 to Day  112) .........................................36
7.1.2.3 Final Visit (Day  112)
..............................................................................36
7.1.3 Additional Care of Subjects after the Stud y
................................ .......................... 36
7.2 Study  Evaluations and Procedures ................................ ................................ ........... 36
7.2.1 Demographic and Other Bas eline Characteristics ................................ ................. 36
7.2.2 Safety ................................ ................................ ................................ ..................... 37
7.2.2.1 Medical and Medication History ............................................................37
7.2.2.2 Physical Examin ation (Including Height and Weight) .......................... 37
7.2.2.3 Adverse Event Collection................................ ................................ .......38
7.2.2.4 Vital Signs ................................ ................................ .............................. 38
7.2.2.5 Clinical L aboratory  Evaluations ................................ ............................. 40
7.2.2.6 Pregnancy  Test ................................ ................................ ....................... 41
Shire CONFIDENTIAL Page 8
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
7.2.2.7 Drug and Alcohol Screen .......................................................................41
7.2.2.8 Serology  Screen ......................................................................................42
7.2.2.9 Electrocardiogram ..................................................................................42
7.2.3 Pharmacokinetic Procedures ..................................................................................43
7.2.3.1 Pharmacokinetic Sample Collection and Handling Procedures .............43
7.2.3.2 Shipment of Plasma Pharmacokinetic Samples .....................................44
7.2.3.3 Plasma Drug Assay  Methodology ..........................................................44
7.2.4 Pharmacod ynamic Assessments ............................................................................44
7.2.4.1 Pharmacod ynamic Sample Collection and Handling Procedures ..........45
7.2.4.2 Shipment of Plasma Pharmacod ynamic Samples ..................................45
7.2.4.3 Plasma Pharmacod ynamic Assay  Methodology ....................................45
7.2.5 Immunogenicit y Testing for Anti -Drug Antibodies ..............................................45
7.2.6 Volume of Blood to Be Drawn from Each Subject ...............................................46
8ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................46
8.1 Defin ition of Adverse Events, Period of Observation, Recording of Ad
verse 
Events .......................................................................................................................46
8.1.1 Severity  Categorization ..........................................................................................47
8.1.2 Relationship Categorization ...................................................................................47
8.1.3 Outcome Categorization ........................................................................................48
8.1.4 Clinical L aboratory  and Other Safet y Evaluations ................................................48
8.1.5 Pregnancy ...............................................................................................................49
8.1.6 Abuse, Misuse, Overdose, and Medication Error ..................................................49
8.2 Serious Adverse Event Procedures ..........................................................................50
8.2.1 Reference Safet y Information ................................................................................50
8.2.2 Reporting Procedures .............................................................................................50
8.2.3 Serious Adverse Event Definition .........................................................................51
8.2.4 Serio
us Adverse Event Collection Time Frame .....................................................51
8.2.5 Serious Adverse Event Onset and Resolution Dates ................................ ............. 51
8.2.6 Fatal Outcome ................................ ................................ ................................ ........ 52
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and Site 
Reporting................................................................................................................52
9DATA MANAGEMENT AND STATISTICAL METHODS
...............................................52
9.1 Data Collection ................................ ................................ ................................ ......... 52
9.2 Clinical Data Management ................................ ................................ ....................... 52
9.3 Data Handling Considerations................................ ................................ .................. 53
9.4 Statistical Analy sis Process ................................ ................................ ...................... 53
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ......54
9.6
Sample Size Calculation and Power Considerations................................ ................ 54
Shire CONFIDENTIAL Page 9
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
9.7 Analy sis Populations/ Analy sis Sets ........................................................................54
9.8 Pharmacokinetic and Pharmacod ynamic Anal yses..................................................54
9.8.1 Pharm acokinetic Analy sis......................................................................................54
9.8.1.1 Statistical Analy sis of Pharmacokinetic Parameters ..............................55
9.8.2 Pharmacod ynamic Anal ysis...................................................................................55
9.8.3 Pharmacokinetic and Pharmacod ynamic Anal ysis................................................56
9.9 Safety  Anal yses........................................................................................................56
9.10 Other Anal yses.........................................................................................................56
9.10.1 Exploratory  Anal ysis.............................................................................................56
10SPONSOR‚ÄôS AND I NVEST IGATOR‚ÄôS RESPONSIBIL
ITIES...........................................57
10.1
Sponsor‚Äôs Responsibilities .......................................................................................57
10.1.1 Good Clinical Practice Compliance .......................................................................57
10.1.2 Indemnity /Liability  and Insurance .........................................................................57
10.1.3 Public Posting of Study  Information ......................................................................57
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................57
10.1.5 Study  Suspension, Ter mination, and Completion ..................................................58
10.2
Investigator‚Äôs Responsibilities .................................................................................58
10.2.1 Good Clinical Practice Compliance .......................................................................58
10.2.2 Protocol Adherence and Investigator Agreement ..................................................58
10.2.3 Documentation and Retention of Records .............................................................59
10.2.3.1 Case Report Forms .................................................................................59
10.2.3.2 Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................59
10.2.3.3 Audit/I nspection .....................................................................................60
10.2.3.4 Financial Disclosure
...............................................................................60
10.3 Ethical Considerations ..............................................................................................60
10.3.1 Informed Consent ................................ ................................ ................................ ...60
10.3.2 Institutional Review Board or Ethics Committee ..................................................61
10.4 Privacy  and Confidentiality ......................................................................................61
10.5 Study  Results/Publication Policy ................................ ................................ ............. 62
11REFERENCES .......................................................................................................................64
12APPENDI CES ................................ ................................ ................................ ........................ 65
Appendix 1 Protocol History ................................ ................................ ..................... 66
Shire CONFIDENTIAL Page 10
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
LIST  OF TABLES
Table 1: Schedule of Assessments ...............................................................................19
Table 2: Detailed Schedule of Assessments
................................................................20
Table 3: Volume of Blood to Be Drawn from Each Subject .......................................46
LIST  OF FIGURES
Figure 1: Study  Design Flow Chart ................................ ................................ .............. 25
Figure 2: Procedures for Screening Vital Signs (Blood Pressure ‚Äì Pulse) ‚Äì
Health y Subject s Only ...................................................................................39
Shire CONFIDENTIAL Page 11
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
ABBREVIA TIONS
ÔÅ¨z
%CV
AETerminal elimination rate constant
Percent c oefficient of variation
Adverse Event
ADA Anti- drug antibody
aPTT
AUC 0-last
AUC 0-‚àûActivated partial thromboplastin time
Area under the concentration- time curve from time zero to the last 
quantifiable concentration in plasma
Area under the concentration -time curve from time zero extrapolated to 
infinity
ÔÅ¢-hCG Beta-Human Chorionic Go nadotropin
BMI
BP
CRABody Mass Index
Blood Pressure
Clinical Research Associate
CRC Clinical Research Center
CRF
cHMWK
Cmax
C1-INHCase Report Form
Cleaved High Molecular Weight Kininogen
Maximum Observed Plasma Drug Concentration
C1 Inhibitor
CHO
CL/FChinese Hamster Ovary
Apparent Clearance
CRO
CV%Contract Research Organization
Coefficient of Variation
DMC Data Monitoring Committee
EC Ethics Committee
ECG
EMAElectrocardiogram
European Medicines Agency
EU European Union
FDA
FSHFood and Drug A dministration
Follicle Stimulating Hormone
GCP Good Clinical Practice
HAE
HBsAg
HCVHereditary  Angioedema
Hepatitis B Surface Antigen
Hepatitis C Virus
Shire CONFIDENTIAL Page 12
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
HIPAA
HIVHealth Insurance Portability  and Accountability  Act
Human Immunodeficiency  Virus
ICH
INR
IgG1International Conference on Harmonisation
International Normalized Ratio
Immunoglobulin G Subclass 1
IRB Institutional Review Board
IRT
KiInteractive Response Technology
Inhibition Constant
MHL W
LLOQ
Mg
mL
mmHG
PD
PK
PMDA
PR
PT
QRS
QT
QTcB
QTcF
RRMinistry  of Health, Labor and Welfare
Lower limit of Quantification
Milligram
Milliliter 
Millimeters Mercury
Pharmacod ynamic
Pharmacokinetic
Pharmaceuticals and Medical Devices Agency
Time elapsed from P wave to R wave in an electrocardiogram
Prothrombin Time
Measure of time for the 3 main deflections in an electrocardiogram
Measure of time between the start of the Q wave and the end of the T 
wave in an electrocardiogram
Measure of time between the start of the Q wave and the end of the T 
wave using Baz ett‚Äôs formula in an electrocardiogram
Measure of time between the start of the Q wave and the end of the T 
wave using Fridericia‚Äôs formula in an electrocardiogram
The time between heart beats in an electrocardiogram
SAE Serious Adverse Event
SAP
SC
SD
TEAE
t¬ΩStatistical Analy sis Plan
Subcutaneous
Standard Deviation
Treatment -Emergent Adverse Event
Terminal half -life
US
Vdz/FUnited States
Apparent Volume of Distribution
6KLUH &21),'(17,$/ 3DJH
3URWRFRO6+3
/DQDGHOXPDE 1RY
678'<6<1236,6
3URWRFROQXPEHU 6+3 'UXJ/DQDGHOXPDE
7LWOHRIWKHVWXG\ $3KDVH2SHQODEHO6WXG\WR(YDOXDWHWKH3KDUPDFRNLQHWLFV6 DIHW\DQG7ROHUDELOLW\DQG
3KDUPDFRG\ QDPLFVRID6LQJOH'RVHRI/DQDGHOXPDE$GPLQLVWHUHG6 XEFXWDQHRXVO\LQ+HDOWK\$GXOW-DSDQHVH
6XEMHFWVDQG0DWFKHG+HDOWK\$GXOW&DXFDVLDQ6XEMHFWV
1XPEHURIVXEMHFWVWRWDODQGIRUHDFKWUHDWPHQWDUP
$WRWDORIKHDOWK\DGXOWPDOHDQGRUIHPDOHVXEMHFWVZLOOE HHQUROOHGLQWRWKHVWXG\FRPSULVLQJVXEMHFWVRI
-DSDQHVHGHVFHQWDQGPDWFKHGQRQ+LVSDQLF&DXFDVLDQVXEMHF WV$VVXPLQJDGURSRXWUDWH DSSUR[LPDWHO\
VXEMHFWVIURPHDFKUDFHHWKQLFLW\DUHH[SHFWHGWRFRPSO HWHWKHVWXG\ 6WXG\VXEMHFWVZKRZLWKGUDZRU
GLVFRQWLQXHHDUO\PD\EHUHSODFHGDWWKHGLVFUHWLRQRIWKHVSRQ VRU 1RQ+LVSDQLF&DXFDVLDQVXEMHFWVZLOOEH
PDWFKHGWRVXEMHFWVRI-DSDQHVHGHVFHQWEDVHGRQVH[PDOH PDOHIHPDOHIHPDOHDJH¬ì\HDUV DQGERG\
PDVVLQGH[¬ì
‚Ä¢7KHVXEMHFWVRI-DSDQHVHGHVFHQWZLOOUHFHLYHRQHVLQJOHPJ VXEFXWDQHRXV6&GRVHRIODQDGHOXPDE
‚Ä¢0DWFKHGQRQ+LVSDQLF&DXFDVLDQVXEMHFWVZLOOUHFHLYHRQHVLQJ OHPJ6&GRVHRIODQDGHOXPDE
,QYHVWLJDWRUV 0'
6LWHVDQG5HJLRQV
:HVW&RDVW&OLQLFDO7ULDOV
&HUULWRV$YH&\SUHVV&$
6WXG\SHULRGSODQQHG
&OLQLFDOSKDVH 
2EMHFWLYHV
3ULPDU\ 7RHYDOXDWHWKHSKDUPDFRNLQHWLF3.SURSHUWLHVRIODQDGHOXPDE DGPLQLVWHUHGDVDVLQJOH6&GRVHRI
PJLQKHDOWK\DGXOWYROXQWHHUVXEMHFWVRI-DSDQHVHGHVFHQW DQGPDWFKHGQRQ+LVSDQLF &DXFDVLDQKHDOWK\
YROXQWHHUVXEMHFWV
6HFRQGDU\ 7RDVVHVVWKHVDIHW\DQGWROHUDELOLW\RIODQDGHOXPDEDGPLQLVWHU HGDVDVLQJOH6&GRVHRIPJWR
KHDOWK\DGXOWYROXQWHHUVXEMHFWVRI-DSDQHVHGHVFHQWDQGPDWFKH GQRQ+LVSDQLF&DXFDVLDQKHDOWK\YROXQWHHU
VXEMHFWV
(QGSRLQWVFRUUHVSRQGLQJWRWKHSULPDU\DQGVHFRQGDU\REMHFWLYHV DUHGHILQHGLQWKHHQGSRLQWVDQGVWDWLVWLFDODQDO\VLV
VHFWLRQRIWKLV6\QRSVLV
5DWLRQDOH
7KLVVWXG\LVEHLQJFRQGXFWHGWRFKDUDFWHUL]HWKH3.DQGSKDUPD FRG\QDPLF3' SURSHUWLHVRIODQDGHOXPDEDQGWR
HYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RIODQDGHOXPDEDGPLQLVWHUH GDVDVLQJOH6&GRVHRIPJLQKHDOWK\VXEMHFWVRI
-DSDQHVHGHVFHQWDQGLQPDWFKHGKHDOWK\QRQ+LVSDQLF &DXFDVLDQ VXEMHFWV 7KHUHVXOWVRIWKLVVWXG\ZLOOEHXVHGWR
VXSSRUWWKHVHOHFWLRQRIWKHGRVLQJUHJLPHQIRUD3KDVHVWXG\ FRQGXFWHGLQ-DSDQHVHSDWLHQWVZLWKKHUHGLWDU\
DQJLRHGHPD+$(
7KH-DSDQHVHUHJXODWRU\DJHQFLHV3KDUPDFHXWLFDOVDQG0HGLFDO' HYLFHV$JHQF\30'$DQGWKH0LQLVWU\RI
+HDOWK/DERUDQG:HOIDUH0+/:UHTXLUHHYLGHQFHWKDWFXUUHQW GDWDLQQRQ-DSDQHVHVXEMHFWVFDQEHH[WUDSRODWHG
WRWKH-DSDQHVHSRSXODWLRQ )RUWKLVUHDVRQWKH6+3VWXG \LVGHVLJQHGWRFKDUDFWHUL]H3.DQG3'SURILOHVDV
ZHOODVWRHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RIODQDGHOXPDE LQ-DSDQHVHDQGPDWFKHGQRQ+LVSDQLF&DXFDVLDQ
KHDOWK\YROXQWHHUVXEMHFWVPPD
Shire CONFIDENTIAL Page 14
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Investigational product, dose, and m ode of administration:
ÔÇ∑Lanadelumab, 300mg SC injection into the abdomen.
ÔÇ∑Lanadelumab is a recombinant, fully human immunoglobulin G subclass 1 (IgG1 ), a kappa light chain 
monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells. Lanadelumab is a potent 
(Ki=125pM) inhibitor of the proteolytic activity of plasma kallikrein. Lanadelumab drug product is a colorless 
to yellow , sterile, preservative -free solution, appearing either clear or w ith sli ght opalescence. The active 
ingredient, lanadelumab, is formulated using the following compendial components: 30mM sodium phosphate 
dibasic d ihydrate, 19.6mM citric acid, 50 mM histidine, 90 mM sodium chloride, 0.01% Polysorbate 80. Each 
vial contains a no minal concentration of 300 mg in 2 mL (150 mg/mL) solution. A 300 mg, single SC dose was 
selected for this study. For each 300 mg dose of lanadelumab, each subject w ill receive a total of 2 mL, which 
will be administered in a single 2 mL SC injection. This study is open -label and does not require the use of a 
placebo.
Methodology:
This study is a Phase 1, open -label, matched -control, single -dose, single -center study to evaluate the PK, safety and 
tolerability and PD of lanadelumab administered to healthy adult volunteer subjects of Japanese descent and 
matched non -Hispanic ,Caucasian healthy adult volunteer subjects .A total of 32 subjects betw een the ages of 18 -55, 
inclusive will be enrolled: 16 non -Hispanic Caucasian subjects and 16 subjects of Japanese descent. Assuming a 
25% dropout rate, approximately 24 subjects (12 subjects from each race/ ethnic ity) are expected to complete the 
study. Non -Hispanic Caucasian subjects w ill be matched to Japanese subjects based on sex (1:1 male: male
,female: 
female), age (¬±5 years), and body mass index (BMI) (¬±15%). For example, a Japanese male, age 40 years, and BMI 
of 22 kg/m2will be matched with a Caucasian male, age 40 ¬± 5 years (35 -45 years [inclusive]), and BMI of 
22¬±15% (18.7 -25.3 kg/m2). 
All subjects will receive a single dose of 300 mg of lanadelumab administered by SC injection into the abdomen.
The study duration will be comprised of a 28 -day screening period, one 5 -day in -house treatment period, and 
multiple out -patient visits ( Day 7 [¬± 1 day ], Day 14 [¬± 1day], Day 21 [¬± 1 day ],Day 28 [¬± 1 day ], Day 42 
[¬± 2 days] , Day 56 [¬± 2 days ], Day  84 [¬± 3 days ]and Day 112 [ ¬± 3 days] )after the single dose of investigational 
product is administered. The maximal total duration of study participation for a subject is approximately 140 days if 
the maximal screening, treatment ,and out -patient durations are used.
Screening Period
Screening will occur within 28 days of the first dose. Subjects will be admitted to the Clinical Research Center 
(CRC) on Day -1.
In-House Conf inement Treatment Period
ÔÇ∑On Day 1, all subjects will receive lanadelumab as a single 300 mg SC injection into the abdomen.
ÔÇ∑All subjects will remain in the CRC until completion of the 96 hour post dose PK sample on Day 5.
Assessments
ÔÇ∑Serial blood samples for PK analysis will be collected for the determination of plasma lanadelumab 
concentrations from Day 1 predose and up to 96 hours post dose during the in -house confinement period 
and up to Day 112 during the out -patient visit period. These blood samples will be collected according to 
the Schedule of Assessments.
Shire CONFIDENTIAL Page 15
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
ÔÇ∑Safety and tolerability including anti -drug antibodies (ADA s) will be determined through assessment of 
treatment -emergent adverse events (TEAEs) and v ital signs, electrocardiogram (ECG) findings, and clinical 
laboratory evaluations on Day 1 predose and up to 96 hours postdose during the in -house confinement 
period and up to Day 112 during the out -patient visit period according to the Schedule of Assessments.
ÔÇ∑Serial blood samples for PD analysis will b e collected for kallikrein activity and for cleaved high molecular 
weight kininogen ( cHMWK)from Day 1 predose and up to 96 hours pos tdose during the in -house 
confinement period and up to Day 112 during the out -patient visit period. These blood samples wil l be 
collected according to the Schedule of Assessments.
Out-Patient Visit Period
Out-patient visits will be completed on the following Study Days:
ÔÇ∑Day 7 (¬± 1 day; ie, Day 6, 7, or 8) 
ÔÇ∑Day 14 (¬± 1 day; ie, Day 13, 14 or 15) 
ÔÇ∑Day 21 (¬± 1 day; i e, Day 20, 2 1 or 22)
ÔÇ∑Day 28 (¬± 2 day; i e, Day 26, 27 28, 29, or 30) 
ÔÇ∑Day 42 (¬± 2 days; ie, Day 40, 41, 42, 43 or 44) 
ÔÇ∑Day 56 (¬± 2 days; i e, Day 54, 55, 56, 57 or 58) 
ÔÇ∑Day 84 (¬± 3 days; i e, Day 81, 82, 83, 84, 85, 86 or 87)
ÔÇ∑Day 112 (¬± 3 days; ie, Day 109, 110, 111, 112, 113, 114 or 115) 
after the single dose of investigational product is administered. Refer to Table 2 for complete details.
Inclusion Criteria:
1. Ability to voluntarily provide written, signed, and dated informed consent as applicable to 
participate in t he study.
2. An understanding, ability, and w illingness to fully comply with study procedures and restrictions.
3. Age 18 -55,inclusive ,at the time of consent. The date of signature of the informed consent is 
defined as the beginning of the Screening Period. This inclusion criterion will only be assessed at 
the first screening visit.
4. Subjects must be either:
a. A subject of Japanese descent born in Japan, who has resided outside of Japan for no 
longer than 5 years and is of Japanese parentage, defined as having 2 J apanese parents 
and 4 Japanese grandparents, all born in Japan
b. A non
-Hispanic ,Caucasian subject who has 2 non -Hispanic ,Caucasian parents and 
4 non -Hispanic ,Caucasian grandparents
5. Male or non -pregnant, non -lactating female who agrees to comply with any applicable 
contraceptive requirements of the protocol or females of nonchildbearing potential.
6. Considered ‚Äúhealthy‚Äù by the investigator. Healthy status is defined by absence of evidence of any 
active or chronic disease following a detailed medical and surg ical history, as well as a complete 
physical examination including vital signs, 12 -lead ECG, hematology, blood chemistry, and 
urinalysis.
Shire CONFIDENTIAL Page 16
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
7. Body  mass index between 18.5 -33kg/m¬≤ , inclusive ,with a body weight ‚â•45kg (99lbs). This 
inclusion criterion will onl y be assessed at the screening visit.
8. Willing and able to consume standardized meals during the confinement period of the study. All 
participants will be required to consume the identical meals on study days when serial PK and PD 
blood samples are collected.
Exclusion Criteria:
1. History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or 
psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the 
action, absorption, or disposition of the inv estigational product, or clinical or laboratory 
assessments.
2. Current or relevant history of physical or psychiatric illness, any medical disorder that may require 
treatment or make the subject unlikely to complete the study, or any condition that presents undue 
risk from the investigational product or procedures.
3. Known or suspected intolerance or hypersensitivity to the investigational product, closely -related 
compounds, or any of the stated ingredients.
4. Significant illness, as judged by the investigator, w ithin 2 weeks of the dose of investigational 
product.
5. Known history of alcohol or other substance abuse within the last year, per the investigator.
6. Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to receiving the 
dose of investigational product.
7. Within 30 days prior to the dose of investigational product:
a. Have used an investigational product (if elimination half -life is <6 days, otherwise 
5half-lives).
b. Have been enrolled in a clinical study (including vaccine studies) tha t, in the 
investigator‚Äôs opinion, may impact this Shire -sponsored study.
8. Confirmed systolic blood pressure (BP) >139mmHg or <89mmHg, and diastolic BP>89mmHg or 
<49mmHg.
9. Twelve-lead ECG values (average of triplicate readings) demonstrating QTc >450msec (males) or 
>470msec (females) at the S creening Visit or Day -1.
10. Positive screen for drugs of abuse (i.e. amphetamines, benzodiazepines, barbiturates, cocaine,
marijuana , opiates, phencyclidine) at Screening ,or drugs of abuse or alcohol on Day -1.
11. Male subje
cts who consume more than 21 units of alcohol per w eek or 3 units per day. Female 
subjects who consume more than 14 units of alcohol per w eek or 2 units per day. One alcohol 
unit=1 beer or 1 w ine (5oz/150mL) or 1 liquor (1.5oz/40mL) or 0.75oz alcohol.
12. Positive HIV, HBsAg, or HCV antibody screen.
13. Use of tobacco in any form (eg, smoking or chewing) or other nicotine -containing products in any 
form (eg, gum, patch, electronic). Ex-users must report that they have stopped using tobacco for at 
least 3 0 days prior to receiving the dose of investigational product.
Shire CONFIDENTIAL Page 17
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
14. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine 
withdrawal headaches. One caffeine unit is contained in the follow ing items: one 6oz (180mL) cup 
of coffee, two 12oz (360mL) cans of cola, one 12 oz cup of tea, and three 1oz (85g) chocolate 
bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine).
15. Current use of any medication (including over -the-counter, herbal, or homeopathic preparat ions; 
with the exception of stable hormonal replacement therapy or hormonal contraceptives). Current 
use is defined as use within 14 days of the dose of investigational product. See Section 5(Prior 
and Concomitant Treatment) for a list of permitted medica tions.
16. Abnorm al laboratory values considered clinically significant, as determined by the investigator at 
Screening or Day -1.
17. History of any clinically significant surgery or procedure w ithin 8 weeks of receiving the dose of 
investigational product, as de termined by the investigator.
Maximum duration of subject involvem ent in the study:
ÔÇ∑Planned duration of screening period: 28 days maximum
ÔÇ∑Planned duration of in -house confinement period: 5 days 
ÔÇ∑Planned duration of out -patient visit period: 107 days 
Endpoints and statistical analysis:
Pharm acokinetic endpoint(s)/parameters:
ÔÇ∑Cmax: Maximum observed plasma drug concentration
ÔÇ∑tmax: Time to reach C maxin plasma
ÔÇ∑AUC 0-last: Area under the concentration -time curve from time zero to the last quantifiable concentr ation in 
plasma
ÔÇ∑AUC 0-‚àû : Area under the concentration -time curve from time zero extrapolated to infinity
ÔÇ∑ ÔÅ¨ z: Terminal elimination rate constant
ÔÇ∑t¬Ω: Terminal half -life
ÔÇ∑CL/F: Apparent clearance
ÔÇ∑Vd z/F: Apparent volume of distribution
Safety is the secondary objective of this study. Safety endpoint(s):
ÔÇ∑Treatment- emergent adverse events : Number and percentage of subjects with TEAEs; severity; seriousness; 
causality; number of TEAEs. 
ÔÇ∑Clinical laboratory results (hematology, clinical chemistry, coagulation and ur inalysis): Changes from 
baseline to post -baseline time points; clinically significant abnormal laboratory assessments.
ÔÇ∑Other: Vital signs ( including BP, pulse, body temperature), 12 -lead ECG ,and physical examination: 
Changes from baseline to post -baseline time points.
ÔÇ∑Anti-drug antibodies
Shire CONFIDENTIAL Page 18
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Analysis populations/analysis sets:
ÔÇ∑Safety population (Safety Analysis Set), defined as all subjects who received at least 1 dose of lanadelumab 
(study drug). All safety analyses will be based on the Safety population/Sa fety Analysis Set.
ÔÇ∑Pharm acokinetic population (PK Analysis Set), defined as all subjects who received at least 1 dose of 
lanadelumab and have at least 1 evaluable postdose PK concentration value. All PK analyses will be based 
on the PK population/PK Analys is Set).
Statistical analysis:
No statistical hypothesis testing is planned. Analysis details will be provided in the study Statistical Analysis Plan 
(SAP), which will be finalized prior to study database lock. Only descriptive analysis will be performed to evaluate 
all primary and secondary endpoints. Summaries will be presented by racial/ethnic group (Japanese vs. 
non-Hispanic Caucasians), and, if appropriate, by time point. All data, including derived data, w ill be presented in 
subject data listings, an d all listings will include subject‚Äôs sex, age, race/ethnicity, and BMI.
ÔÇ∑No interim analysis or Data Monitoring Committee (DMC) is planned.
Shire CONFIDENTIAL Page 19
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
STUDY  SCHEDULE(S)
Table 1: Schedule of Assessments
Visit Screening In-
House Treatment Per iodOut-Patient 
Visitsa/ Early 
Discontinuationb
Study Day ‚Äì28 to -02 -1 1 2 3 4 5
Informed consent X
Inclusion/exclusion criteria X X
Demography and medical/medication 
historyX Xc
Physical examination X X X X
Vital signs (blood pressure, pulse) 
supine d X X X X X X X X
Body temperature (oral) X X X
Height, Weight and BMIe,fX X X X
Electrocardiogram (12 -lead)dXgXgX X X X X X
Biochemistryh, hematology, and 
urinalysis X X X X X
PT, aPTT, INR X X X X
HIV, HBsAg, and HCV antibodies X
Serum Pregnancy test (all females ) dX X X X
FSH ( females only) X
Urine drug and alcohol (breath test) 
screening i X X Xj
Investigational Product administration X
Pharmacokinetic blood sampling dX X X X X Xj
Anti-drug antibody testing dX X
Pharmacodynamic blood samplingdX X X X X Xj
Check -in to the CRC X
Discharge from the CRC X
In-house confinement X X X X X
Out-patient visits X X
Adverse events/serious adverse events X X X X X X X X
Concomitant medication X X X X X X X X
HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus
aThere will be multiple out -patient v isits on: Day 7 (¬± 1 day), Day 14 (¬± 1 day), Day 21 (¬± 1 day), Day 28 (¬± 1 day), Day 42 (¬± 
2 days), Day 56 (¬± 2 days), Day 84 (¬± 3 days) and End of Study Day 112 (¬± 3 days), after the dose of investigational product
is administered on Day 1. Refer to Table 2 for complete details.
bIn the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete
these assessments.
cMedical history and medication history review only
dSee Table 2 for detailed co llection time points
eHeight will be recorded at the Screening Visit only
fBMI criteria for eligibility will be calculated at the Screening Visit.
gECGs will be performed in triplicate at Screening and Day -1 only. Thereafter, all subsequent ECGs will be single recordings
hThyroid function tests (TSH, T3, T4) will be collected as part of the biochemistry panel at Screening only.
iDrugs of abuse at screening, and drugs of abuse and alcohol (breath test) on Day -1 and at all out-patient visits. 
jNo PK or PD sample, or urine drug or alcohol screen should be collected for early discontinuation.
Shire CONFIDENTIAL Page 20
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Table 2: Detailed Schedule of Assessments
In-
House Treatment Period Out-Patient Visits
Study Day Day 1 Day 
2Day 
3Day 
4Day 
5Day 
7¬±1Day
14¬±1Day
21¬±1Day
28¬±2Day
42¬±2Day
56¬±2Day
84¬± 3Day
112¬±3
End of 
Study 
(or Early 
Term .a)
Hour (relative to 
dosing time)Pre
dose0 1h 2h 4h 6h 8h 12h 24h 48h 72h 96h
Physical 
examination X X X X X X X X X
Vital s igns 
(blood pressure, 
pulse) supineXbX X X X X X X X X X X X X X X X X X
Body temperature 
(oral)X X X X X X X X X
Weight X X X X X X X X X
Electrocardiogram 
(12-lead) c XbX X X X X X X X X X X X X X X
Biochemistry, 
hematology, and 
urinalysisX X X X X X X X X X
PT, aPTT, INR X X X X X X X X X
Serum Pregnancy 
(all women)X X X X X X X X X
Urine drug and 
alcohol (breath test) 
screenX X X X X X X Xd
Investigational 
Product
administrationX
Pharmacokinetic 
blood samplingXbX X X X X X X X X X X X Xd
Pharmacodynamic 
blood samplingXbX X X X X X X X X X X X Xd
Anti-drug antibody 
samplingXbX X X X
Adverse X X X X X X X X X X X X X X X X X X X X
Shire CONFIDENTIAL Page 21
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Table 2: Detailed Schedule of Assessments
In-
House Treatment Period Out-Patient Visits
Study Day Day 1 Day 
2Day 
3Day 
4Day 
5Day 
7¬±1Day
14¬±1Day
21¬±1Day
28¬±2Day
42¬±2Day
56¬±2Day
84¬± 3Day
112¬±3
End of 
Study 
(or Early 
Term .a)
Hour (relative to 
dosing time)Pre
dose0 1h 2h 4h 6h 8h 12h 24h 48h 72h 96h
events/serious 
adverse events 
Concomitant 
medication X X X X X X X X X X X X X X X X X X X X
aIn the event a subject is prematurely discontinued from the study or withdraws, every attempt should be m ade to complete these assessments .
bThese assessments should be performed within 60 minutes prior to dose administration.
cECG‚Äôs will be performed as single records at each timepoint.
dNo PK or PD sample, or urine drug or alcohol screen should be collec ted for early discontinuation.
Shire CONFIDENTIAL Page 22
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
1 BACKGROUND INFORMATI ON
Lanadelumab (SHP643, formerl y DX -2930) is a recombinant, fully  human immunoglobulin G 
subclass 1 (IgG1) , a kappa light chain monoclonal antibody  expressed in Chinese Hamster Ovary  
(CHO) cells that has been studied in a double -blind, pivotal Phase 3 study  (Study  DX-2930- 03), 
and is being studied in an on -going open
-label Phase 3 study  (Study  DX-2930 -04) to determine 
if it is safe and effective for the prevention of angioedema attacks in patients with hereditary  
angioedema (HAE).
This study  is being conducted to evaluate the PK, safet y and tolerability, and pharmacod ynamic 
(PD) of lanadelumab administered as a single subcutaneous (SC) dose of 300 mg in a Japanese 
population in comparison with a single SC dose of 300 mg in a matched non -Hispanic ,
Caucasian population.
For further details see the current lanadelumab Investigator ‚ÄôsBrochure.
1.1 Indication and Current Treatment Options 
Lanadelumab is in development for prevention of angioedema attacks in patient s with Ty pes I or 
II HAE, a rare and potentially  life-threatening disease.
Lanadelumab is a recombinant, fully  human IgG1, kappa light chain, monoclonal antibody  
expressed in CHO cells. Lanadelumab is a potent (Ki = 125 pM) inhibitor of the proteol ytic 
activity of plasma kallikrein.
The activity , potency  and,specificit y of lanadelumab have been demonstrated in vitro and ex 
vivo and ha vebeen confirmed in clinical studies.
Hereditary  angioedema is a long -term, debilitating, and potentially  life-threatening disease 
caused b y mutations in the C1 -inhibitor (C1
-INH) gene, resulting in deficiency o rdysfunction of 
C1-INH protein. HAE manifests clinicall y as unpredictable, intermittent attacks of SC or 
submucosal edema of the face, lary nx, gastrointestinal tract, limbs, and/or genitalia ( Zuraw, 
2008). Swelling may  last up to 5 day s; most patients suffer multiple attacks per y ear.HAE is an 
orphan disease. Its exact prevalence is unknown; however, current estima
tes range from 1 per 
10,000 to 1 per 150,000 persons, with many  authors agreeing that 1 per 50,000 is likely  the 
closest estimate ( Bygum, 2009 ; Goring et al., 1998 ; Lei et al., 2011 ; Nordenfelt et al., 2014 ; 
Roche et al., 2005 ).
Currently ,HAE drugs are indicated either for prophy laxis against attacks or f or treatment of 
acute attacks. Acute treatments include purified, plasma -derived C1- INH, recombinant C1 -INH, 
a plasma kallikrein inhibitor, and a brad ykinin type 2 (B2) receptor antagonist. While acute 
treatments are effective at resolving the s ymptoms of acute attacks, they  do not prevent attacks 
and thus leave patients at risk of developing debilitating and potentiall y life -threatening attacks.
Agents used for proph ylaxis include purified plasma -derived C1- INH, attenuated androgens, and 
antifibrinoly tic agents.
Shire CONFIDENTIAL Page 23
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
These currentl y available therapies represent an important addition to the therapeutic options for 
HAE patients; however, there remains a need for more optimal prophylactic therap y with 
improved efficacy , longer half -lives and more convenient admin istration frequencies.
1.2 Product Background
1.2.1 Preclinical Information
Nonclinical studies to evaluate the pharmacokinetic ( PK)and toxicology  of sy stemicall y 
administered lanadelumab have been completed in rats and cy nomolgus monkey s.
Single -dose, 28 -day and 6 -month multidose studies of sy stemically  administered lanadelumab in 
cynomolgus monkey s did not identify toxicologically  significant effects at doses up to 
50 mg/kg administered weekl y by SC injections. Studies to evaluate male and female fertility  in 
thecynomolgus monkey , at similar dose levels, revealed no adverse treatment -related findings.
There were no adverse treatment -related findings after 28 day s of IV dosing up to 50 mg/kg
In addition, results from a separate lanadelumab single- dose SC injectio n study  to evaluate 
potential toxicity  and toxicokinetic profiles in Sprague -Dawley  rats, showed lanadelumab to be 
well-tolerated at up to 50 mg/kg.
Refer to the lanadelumab I nvestigator‚Äôs Brochure for further information.
1.2.2 Clinical Information
The clinical development program for lanadelumab consists of two completed Phase 1 studies: a 
single -ascending dose Phase 1a Stud y, DX2930 01 in healthy adult subjects and a multiple -
ascending dose andPhase 1b Study  DX2930 02 in adult subjects with HAE; a completed p ivotal, 
double -blind, placebo -controlled Phase 3 Study  DX2930 03 (HELP Study¬Æ),and one ongoing 
open -label Phase 3 Study DX2930 04 (HELP Study  Extension‚Ñ¢) in adolescents and adult 
subjects with HAE.
Alway s refer to the latest version of the lanadelumab Investigator‚Äôs Brochure for the overall 
risk/benefit assessment and the most accurate and current information regarding the metabolism, 
pharmacokinetics, efficacy , and safet y of lanadelumab.
1.3
Risk/Benefit and Ethical Assessment
There is no anticipated benefit from taking part in this study .
2 STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
This study  is being conducted to characterize the PK and PD properties of lanadelumab and to 
evaluate the safet y and tolerability of lanadelumab administered as a single SC dose of 300 mg in 
healthy  subjects of Japanese descent and in matched healthy  non- Hispanic ,Caucasian subjects.
Shire CONFIDENTIAL Page 24
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
The results of this study  will be used to support the selection of the dosing regimen for a Phase 3 
study  conducted in Japanese patients with HAE.
The Japanese regulatory agencies, Pharmaceuticals and Medical Devices Agency  (PMDA) ,and 
the Ministry  of Health, Labor and Welfare (MHLW), require evidence that current data in 
non-Japanese subjects can be extrapolated to the Japanese population. For this reason, the 
SHP643 -101 study  is designed to characterize PK and PD profiles, as well as to evaluate the 
safet y and tolerability of lanadelumab in Japanese and matched non-Hispanic, Caucasian healthy  
volunteer subjects.
A number of scientific publica tions have suggested the similarity  of the PK profiles of 
monoclonal antibody
 products between ethnic healthy  subjects groups ( Chiba et al., 2014 ; 
Morrison et al., 2015 ), thereb y supporting the extrapolation of safet y and efficacy  data from 
other ethnic groups to Japanese pa tients with HAE. This study  is aimed to specificall y confirm 
this observation for lanadelumab administered as a single SC 300 mg dose. The study  can be 
conducted in a clinical research facilit y that is located outside of Japan as long as steps are taken 
toensure the Japanese subjects are verified as Japanese ,as noted in Inclusion Criterion 4.
2.2
Study Objectives
2.2.1 Primary Objectives
To evaluate the PK properties of lanadelumab administered as a single SC dose of 300 mg in 
healthy  adult volunteer subjects of Ja panese descent and matched non -Hispanic, Caucasian 
healthy  volunteer subjects.
2.2.2 Secondary Objectives
To assess the safet y and tolerability of lanadelumab administered as a single SC dose of 300 mg 
to healthy  adult volunteer subjects of Japanese descent and matched, non- Hispanic Caucasian 
healthy  volunteer subjects.
2.2.3 Exploratory Objectives
To explore the PD properties of lanadelumab including plasma kallikrein activity  and cleaved 
high molecular weight kininogen (cHMWK) plasma levels after a single SC dose of 300 mg of 
lanadelumab administered to healthy adult volunteer subjects of Japanese descent and matched 
non-Hispanic, Caucasian healthy  volunteer subjects.
Endpoints corresponding to the primary  and secondary  objectives are defined in the 
Study Synopsis, and endpoints corresponding to the exploratory objective are defined in 
Section 9.8.2.
Shire CONFIDENTIAL Page 26
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
3.2 Duration and Study Completion Definition
The subject‚Äôs maximum duration of participation is expected to be appro ximately  140 day s.The 
study  is expected to be completed in approximately  20 weeks. 
The Study  Completion Date is defined as the date the final subject completes their final 
protocol -
defined assessment. Please note that this includes the follow- up visit or contact, 
whichever is later. The Study Completion Date is used to ascertain timing for study  results 
posting and reporting.
3.3 Sites and Regions
This study  will be performed at one study site within the United States.
4 STUDY POPULATION
Each subject must participate in the informed consent process and provide written informed 
consent before an y procedures specified in the protocol are performed.
4.1 Inclusion Criteria
The subject will not be considered eligible for the study  without meeting all of the criteria below.
Subjects cannot be enrolled before all inclusion criteria (including test results) are confirmed.
1.Ability  to voluntaril y provide written, signed, and dated informed consent as applicable to 
participate in the stud y.
2. An understanding, ability, and willin gness to full y comply  with study  procedures and 
restrictions.
3.Age 18 -55,inclusive , at the time of consent. The date of signature of the informed consent is 
defined as the beginning of the Screening Period. This inclusion criterion will only  be 
assessed at the first screening visit.
4.Subjects must be either:
a.A subject of Japanese descent born in Japan, who has resided outside of Japan 
for no longer than 5 years and is of Japanese parentage, defined as having 
2Japanese parents and 4 Japanese grandparents, al l born in Japan.
b.A non-Hispanic ,Caucasian subject who has 2 non-Hispanic ,Caucasian 
parents and 4 non -Hispanic ,Caucasian grandparents.
5.Male or non- pregnant, non -lactating female who agree s to compl y with an y applicable 
contraceptive requirements of the protocol or females of non- childbearing potential.
Shire CONFIDENTIAL Page 27
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
6.Considered ‚Äúhealthy ‚Äù by the investigator. Health y status is defined by  absence of evidence of 
any active or chronic disease following a detailed medical and surgical history , as well as a 
complete ph ysical examination including vital signs, 12 -lead ECG, hematology , blood 
chemistry , and urinal ysis.
7.Body mass index between 18.5 -33kg/m¬≤ , inclusive ,with a bod y weight ‚â•45kg (99lbs). This 
inclusion criterion will only  be assessed at the screening visit.
8.Willing and able to consume standardized meals during the confinement period of the stud y. 
All participants will be required to consume the identical meals on study  days when serial PK 
and PD blood samples are collected.
4.2
Exclusion Criteria
Subjects are excluded f rom the study  if an y of the following exclusion criteria are met:
1.History  of any  hematological, hepatic, respiratory, cardiovascular, renal, neurological or 
psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the 
action, absorption, or disposition of the investigational product, or clinical or laboratory  
assessments.
2.Current or relevant history  of physical or ps ychiatric illness, any medical disorder that may 
require treatment or make the subject unlikel y to complete the study , or any  condition that 
presents undue risk from the investigational product or procedures.
3.Known or suspected intolerance or h ypersensitivity to the investigational product, closely-
related compounds, or any  of the stated ingredients.
4.Significant illness, as judged by  the investigator, within 2 weeks of the dose of 
investigational product.
5.Known history  of alcohol or other substance abuse within the last y ear, per the investigator.
6.Donation of blood or blood products (eg, plasma or platelets) wit hin 60 day s prior to 
receiving the dose of investigational product.
7.Within 30 day s prior to the dose of investigational product:
a. Have used an investigational product (if elimination half- life is <6 day s, 
otherwise 5 half -lives).
b. Have been enrolled in a cli nical study  (including vaccine studies) that, in 
the investigator‚Äôs opinion, may  impact this Shire -sponsored study .
8.Confirmed sy stolic blood pressure (BP) >139mmHg or <89mmHg, and diastolic BP
>89mmHg or <49mmHg.
9.Twelve -lead ECG values (average of triplica te readings) demonstrating QTc >450msec 
(males) or >470msec (females) at the S creening Visit or Day  -1.
10.Positive screen for drugs of abuse (ie ,
amphetamines, benzodiazepines, barbiturates, cocaine, 
marijuana, opiates, phency clidine) at Screening ,or drugs of abuse or alcohol on Day  -1.
Shire CONFIDENTIAL Page 28
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
11.Male subjects who consume more than 21 units of alcohol per week or 3 units per day .
Female subjects who consume more than 14 units of alcohol per week or 2 units per day . One
alcohol unit=1 beer or 1 wine (5oz/150mL ) or 1 l iquor (1.5oz/40mL ) or 0.75oz alcohol.
12.Positive HI V, HBsAg, or HCV antibody  screen.
13.Use of tobacco in an y form (eg, smoking or chewing) or other nicotine -containing products 
in any  form (eg, gum, patch, electronic). Ex-users must report that they  have stopp ed using 
tobacco for at least 3 0 day s
prior to receiving the dose of investigational product.
14.Routine consumption of more than 2 units of caffeine per day  or subjects who experience 
caffeine withdrawal headaches. One caffeine unit is contained in the following items: one 
6oz (180mL ) cup of coffee, two 12oz (360mL) cans of cola, one 12oz cup of tea, and three 
1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain 
caffeine.
15.Current use of an y medication (including over -the-counter, herbal, or homeopathic 
preparations; with the exception of hormonal replacement therap y or hormonal 
contraceptives). Current use is defined as use within 14 day s of the dose of investigational 
product. See 
Section 5 (Prior and Concomitant Treatment) for a list of permitted medications.
16.Abnormal laboratory  values considered clinicall y significant , as determined by  the 
investigator at Screening or Day  -1.
17.History  of any  clinicall y significant surgery  or procedure within 8 weeks of receiving the 
dose of investigational product, as determined b y the investigator.
4.3
Restrictions 
1.Subjects should refrain from strenuous phy sical exercise 48 hours prior to admission to the 
clinical research center (CRC) and during the in -house stay s at the CRC.
2.Subjects should refrain from alcohol 48 hours prior to admission to the CRC and during the 
in-house stay  at the CRC (Day  1-5) and 48 hours prior to each outpatient visit during the 
study .
3.Subjects must refrain from use of tobacco or an y products containing nicotine wit hin 3 0 day s
of Day  1 of the treatment period through the completion of the last treatment period.
4.Subjects should refrain from taking or regularl y using an y medication (including over -the 
counter multivitamin, herbal, or homeopathic preparations) with the exception of those listed 
in Section 5.2.1 from 14 day s prior to receiving the dose of the investigational product 
through the completion of the discharge assessments and procedures.
5.Subjects should refrain from foods or beverages containing caffeine/xanth ine 48 hours prior 
to admission to the CRC and during the in -house stay  at the CRC.
6.
Subjects will be required to follow standardized meal schedules and eat the meals provided 
by the site while housed in the CRC. No outside food or beverages (including gum, mints, 
etc.) will be permitted. Menus will be identical for all subjects at the CRC. Copies of the 
menus will be provided to the sponsor for approval prior to the start of the study . 
Shire CONFIDENTIAL Page 29
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
While confined, the total daily  nutritional composition should be approx imately  50% 
carboh ydrate, 35% fat, and 15% protein. The daily caloric intake per subject should not 
exceed approximately 3200 kcal.
4.4 Reproductive Potential
4.4.1 Female Contraception
Sexually  active females of childbearing potential should be using an acceptable form of 
contraception. Females of childbearing potential must be advised to use acceptable 
contraceptives throughout the study period and for 112 day s following the dose of investigational 
product. If hormonal contraceptives are used, they should be admini stered according to the 
package insert. Females of childbearing potential who are not currently  sexually  active must 
agree to use acceptable contraception, as defined below, if they  become sexually  active during 
the period of the stud y and 112 days followi ng the dose of investigational product. 
Female subjects should be either:
ÔÇ∑Postmenopausal (12 consecutive months of spontaneous amenorrhea and follicle stimulating 
hormone 
(FSH)result in the laboratory  post -menopausal range at Screening )
ÔÇ∑Surgicall y steril e (having undergone one of the following surgical acts: hy sterectom y, 
bilateral tubal ligation, bilateral oophorectom y or bilateral salpingectom y)and,at least ,
6weeks post -sterilization, or
ÔÇ∑Females of childbearing potential with a negative urine and/or serum beta-Human chorionic 
gonadotropin ( ÔÅ¢-hCG )pregnancy test at the Screening Visit and Day -1. Females of 
childbearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraceptio n.
Acceptable methods of contraception are:
ÔÇ∑Intrauterine devices plus condoms
ÔÇ∑Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
ÔÇ∑Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the first dose of investigational product, plus condoms. Note: If subject 
becomes sexually  active during the study , they  should use one of the other acceptable 
methods noted above in addition to the hormonal contraceptive until it has be en stabilized for 
30days.
4.4.2 Male Contraception
Male subjects must be advised to use acceptable contraceptives throughout the study  period and 
for 1 60days following the dose of investigational product. Male subjects must be advised not to 
donate sperm durin g the course of the stud y and within 1 60days of the dose of investigational 
product. Acceptable methods of contraception for male subjects include:
ÔÇ∑Double-barrier methods (eg, Condoms and diaphragms with spermicidal gel or foam).
Shire CONFIDENTIAL Page 30
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
4.5 Discontinuation of Subjec ts
A subject may  withdraw from the study  at any  time for an y reason without prejudice to their 
future medical care b y the physician or at the institution. The investigator or sponsor may  
withdraw the subject at any  time (eg, in the interest of subject safe ty). The investigator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational product is discontinued, regardless of the reason, the early withdrawal 
evaluations listed in Tab le 2are to be performed as completely  as possible. Whenever possible, 
all discontinued subjects should also undergo the protocol
-specified follow -up(ie Day  112/ End 
of Study  Visit) . Comments (spontaneous or elicited) or complaints made b y the subject mus t be 
recorded in the source documents. The reason for termination and date of stopping 
investigational product must be recorded in the case report form ( CRF )and source documents.
Subjects who withdraw or discontinue early may be replaced (if needed) at the discretion of the 
sponsor , to ensure that approximately 24 subjects (12 from each race/ethnicity ) complete the 
study .
4.5.1 Reasons for Discontinuation
The reason for withdrawal must be determined b y the investigator and recorded in the subject‚Äôs 
medical recor d and on the CRF. If a subject is withdrawn for more than 1 reason, each reason 
should be documented in the source document and the most clinically  relevant reason should be 
entered on the CRF.
Reasons for discontinuation include but are not limited to:
ÔÇ∑Adverse event (AE)
ÔÇ∑Protocol deviation
ÔÇ∑Withdrawal by  subject
ÔÇ∑Lost to follow -up
ÔÇ∑Other Bygum, 2009
4.5.2 Subjects ‚ÄúLost to Follow-up‚Äù Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an ysubject lost to follow -up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject‚Äôs last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations.
Shire CONFIDENTIAL Page 31
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
5 PRIOR AND CONCOMITAN T TREATMENT
5.1 Prior Treatment
Prior treatment includes all treatment (including but not limited to herbal treatments, vitamins,
and nonpharmacological treatments such as ps ychotherap y as appropriate) received within 
30 day s (or PK equivalent of 5 half -lives, whichever is longer) of the date of the dose of 
investigational product. Prior treatment information must be recorded on th e appropriate CRF 
page.
5.2 Concomitant Treatment 
Concomitant treatment refers to all treatment taken between the date of the administration of 
investigational product and the end of the follow -up period (ie Day  112/ End of Study Visit) , 
inclusive. Concomitant treatment information must be recorded on the appropriate CRF page.
5.2.1 Permitted Treatment
Subjects should refrain from taking an y medications (excluding those medications listed below) 
during the course of the study . Any medication which is considered nece ssary  for the subject‚Äôs 
safet y and well -being may  be given at the discretion of the investigator. The administration of all 
medications (including investigational products) must be listed on the appropriate CRF page.
Medications permitted during the stud y are listed below:
ÔÇ∑Hormonal contraceptives for females of childbearing potential administered according to the 
package insert (see Section 
4.4.1)
ÔÇ∑Stable hormone r eplacement therap y ‚â•3 months prior to dose of investigational p roduct
ÔÇ∑Occasional use of a nonsteroidal anti -inflammatory  drug as prescribed by  the principal 
investigator or delegate.
6 INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The test prod uct is lanadelumab (SHP643, formerly  known as DX -2930), which will be provided 
in 300mg vials for SC injection. Additional information is provided in the current lanadelumab 
Investigator‚Äôs Brochure.
6.1.1 Blinding the Treatment Assignment
Not Applicable.
6.2 Adminis tration of Investigational Product
6.2.1 Allocation of Subjects to Treatment
This is an open -label single -center study .
Shire CONFIDENTIAL Page 32
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Subject (screening) numbers are assigned to all subjects as they consent to take part in the study . 
The subject number is assigned to subject s according to the sequence of presentation for study  
participation. This will be a 4 -
digit number starting at 0001.
A 4-digit subject number, starting at 1001, will be allocated immediatel y prior to dosing after 
eligibility  has been determined. If a subje ct number is allocated incorrectly, the study  monitor 
must be notified as soon as the error is discovered. Once a subject number has been assigned, 
that number must not be used again if, for example, a subject is withdrawn from the study. For 
enrolled subj ects, the subject number will be the identify ing number used throughout the CRF.
6.2.2 Dosing
After the subject complete sthe screening process and is found to be eligible for dosing, the 
subject will receive a single 300mg lanadelumab SC injection in the abdome n on Day  1 of the 
in-house confinement period.
A full description of the details and preparation and administration of investigational product 
will be provided in a Pharmacy  and Investigational Product Administration Manual, provided 
separately .
6.2.3 Unblindin g the Treatment Assignment
Not Applicable.
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling
Labels containing study  information and pack identification are applied to the investigational 
product container.
All investigational product is labeled with a m inimum of the protocol number, dosage form
(including product name), directions for use, storage conditions, expiry  date (if applicable), Lot 
number and/or packaging reference, the statements ‚ÄúFor clinical trial use only ‚Äù and/or 
‚ÄúCAUTION: New Drug ‚ÄìLimited by Federal (or US) Law to Investigational Use,‚Äù and ‚ÄúKeep 
out of reach of children,‚Äù and the sponsor's name and address.
Space is allocated on the label so that the site representative can record a unique subject 
identified and initials.
Additional labe ls (eg, those used when dispensing marketed product) may , on a case
-by-case 
basis, be applied to the investigational product in order to satisfy  local or institutional 
requirements, but must not:
ÔÇ∑Contradict the clinical study  label
ÔÇ∑Obscure the clinical stu dy label
ÔÇ∑Identify  the study  subject by  name
Shire CONFIDENTIAL Page 33
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Additional labels may  not be added without the sponsor‚Äôs prior full agreement.
6.3.2 Packaging
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.3 Stora ge
The investigator has overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location. L imited responsibility  may  be delegated to the pharmacy  or 
member of the stud y team, but this delegation must be docume nted. Investigational products are 
distributed by  the pharmacy  or nominated member of the study  team. The pharmacist/nominated 
team member will enter the unique subject identifier and initials on the investigational product 
bottle/carton labels as they are distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by using either an 
in-house sy stem, a mechanical recordin g device such as a calibrated chart recorder, or b y manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ul timate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by  the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
6.4 Drug Accountability
Investi gators will be provided with sufficient amounts of the investigational product to carry  out 
this protocol for the agreed- upon number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment con tent and 
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destroy ed must be maintained as detailed further in this section.
The investigator has overall responsibility  for administering investigational product. W here 
permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is adequatel y 
trained in the protocol and who works under the direct supervision of the investigator. This 
delegation must be documented in the applicable study  delegat ion of authority  form.
Shire CONFIDENTIAL Page 34
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
The investigator or his/her designee (as documented by  the investigator in the applicable study  
delegation of authorit y form) will administer the investigational product only to subjects 
included in this study  following the procedure s set out in the study  protocol. Each subject will be 
given onl y the investigational product carry ing his/her treatment assignment. All administered 
investigational product will be documented on the CRFs and/or other investigational product 
record.
No investigational product stock or returned inventory  from a Shire -sponsored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent b y the 
sponsor. If such transfer is authorized by
 the sponsor, all applicable local, sta te, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.
At the end of the stud y, or as instructed b y the sponsor, all unused stock, and empty /used 
investigational product packaging are to be sent to a nominated contractor on behalf of the 
sponsor. Investigational products being returned to the sponsor‚Äôs designated contractors must be 
counted and verified b y clinical site pe rsonnel and the sponsor (or designated contract research 
organization [CRO]). For unused supplies where the originally  supplied tamper -evident feature is 
verified as intact, the tamper- evident feature must not be broken, and the labeled amount is to be 
documented in lieu of counting. Shipment return forms, when used, must be signed prior to 
shipment from the site. Validated electronic return sy stems (ie, interactive response technology  
[IRT]) do not require a shipment form. Returned investigational products must be packed in a 
tamper -evident manner to ensure product integrity . Contact the sponsor for authorization to 
return an y investigational product prior to shipment. Shipment of all returned investigational 
product must comply  with local, state, and natio nal laws. 
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational produ cts delivered with those used and returned. All investigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor‚Äôs 
satisfaction .
6.5 Subject Compliance
Compliance must be assessed by  observation of dosing by  the investigator or designee. The 
investigator/nominated person will record details on the drug accountability  log(s) and/or source 
document s. In addition, details of the dosing time (time, date, dose level) will be captured in the 
appropriate CRF.
6.6 Retention of Bioavailability and Bioequivalence Testing Samples
Not applicable.
Shire CONFIDENTIAL Page 35
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
7 STUDY PROCEDURES
7.1 Study Schedule
See Table 1 and Table 2 for study  procedures. The following ‚Äúpriorit y order‚Äù will be in effect 
when more than 1 procedure or assessment is required at a particular time point.
ÔÇ∑Spontaneous or solicited AE reporting
ÔÇ∑Electrocardiogram (ECG)
ÔÇ∑Vital signs
ÔÇ∑Clinical laboratory  tests 
ÔÇ∑Pharmacokineti c blood sampling
ÔÇ∑Anti- drug antibody  (ADA) sampling
ÔÇ∑Pharmacod ynamic blood sampling
ÔÇ∑Physical examination
NOTE: Blood sampling for PK and PD evaluation must be performed at the precise 
protocol -scheduled time. Actual sampling time(s) must be accuratel y recor ded in the source 
document and appropriate CRF.
7.1.1 Screening Period 
Screening procedures must be completed within 28 days prior to receiving the dose of 
investigational product. All screening assessments and procedures are to be performed b y the 
principal investigator or a qualified designee. See Table 1 for a complete list of screening 
procedures to be performed.
Written, signed, and dated informed consent from the subject prior to the performance of an y 
study -related procedures must be obtained by  the princ ipal investigator or a designee. A cop y of 
the signed informed consent form must be given to the subject for their records.
7.1.1.1 Screening Failure
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been enrolled or administered 
investigational product.
7.1.1.2 Rescreening of Subjects
Subjects who fail to meet all inclusion/exclusion criteria will not be permitted to be rescreened 
for the stud y at an y point.
Shire CONFIDENTIAL Page 36
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Eligible su bjects who meet all inclusion/exclusion criteria but are unable to participate in the 
study  due to scheduling conflicts/timing may  be rescreened based on investigator discretion and 
sponsor approval should their availability  to participate fall outside the screening window. In 
these cases, a new screening number must be assigned for each subject who is rescreened and a 
new informed consent form must be signed.
7.1.2 Treatment Period 
7.1.2.1 In-house Confinement Period (Day 1 to Day 5)
Study  assessments for Day  1 to Day  5 of the in- house confinement treatment period are outlined 
in Table 1 and Table 2 .Administration of investigational product will occur on Day  1 (for all 
study  subjects) of the in
-house confinement treatment period.
Subjects will be discharged from the CR C following completion of the last study  assessment on 
Day 5 of the in -house confinement period.
7.1.2.2 Out-Patient Visit Period (Day 6 to Day 112)
The out -patient visit period for this protocol begins following discharge on Day  5, and continues
until the last ou t-patient visit (Day  112 ¬± 3 day s). During this out -patient period, subjects will 
return to the CRC for 8 visits in order to complete scheduled assessments and procedures (as 
detailed in Table 
1and Table 2).
These assessments include: blood and urine 
samples for clinical safet y labs including pregnancy 
for all females, blood samples for PK and PD assessments, urine for drug and alcohol testing, 
physical examination (including weight ), vital signs (including BP, pulse ,and oral bod y 
temperature) , ECG, serio us adverse events ( SAEs ) , AEs, and concomitant medications.
7.1.2.3 Final Visit (Day 112)
The final visit will be the Day  112 (¬± 3 day s) out -patient visit. This visit also serves as the 
follow -up visit for this study . Refer to Table 1 and Table 2 for outlined study assessments and 
procedures. All AEs and SAEs that are not resolved by  the last study  visit (Day  112) will be 
followed to closure (see Section 8.1).
7.1.3
Additional Care of Subjects after the Study
No aftercare is planned for this study .
7.2 Study Evaluations and Procedures
7.2.1 Demographic and Other Baseline Characteristics
Demographic information will be collected at the initial screening visit. Information to be 
collected will include:
ÔÇ∑Date of birth
ÔÇ∑Sex
ÔÇ∑Race and ethnicity
Shire CONFIDENTIAL Page 37
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
7.2.2 Safety
The name and address of each third -party vendor (eg, clinical laboratory ) used in this study  will 
be maintained in the investigator‚Äôs and sponsor‚Äôs files.
Actual safety  assessment times will be monitored and recorded. The sponsor‚Äôs expectation is that 
the investigator will ensure that every  effort is made to perform all assessments at the precise 
protocol -scheduled time. Any  safet y assessment that deviates from the scheduled assessment 
time set forth in the protocol by  more than ÔÇ±15 minutes will be considered a protocol deviation.
Adverse event s, prior medication, and concomitant medication use will be assessed and 
monitored from the time the subject signs the informed consent form to completion of the study  
(including to time of screen failure or drop out/discontinuation). During the study , subject safet y 
will be closely  monitored by  vital sign measurements, ECG measurements, clinical safet y labs ,
and phy sician oversight. 
7.2.2.1 Medical and Medication History
A complete medical and medication history will be collected at the screening visit and time 
points described in Table 1 and Table 2 by a qualified licensed ph ysician, phy sician‚Äôs assistant, 
or a nurse practitioner. The medical history  will be reviewed and recorded in the source records 
(and entered in the CRF) , which will includ e :
ÔÇ∑Recent use of me dication (30 day s prior to entering the screening period)
ÔÇ∑History  of respiratory , cardiovascular, renal, gastrointestinal, hepatic, endocrine, 
hematological, neurological, psy chiatric, and other diseases
7.2.2.2 Physical Examination (Including Height and Weight)
Acomplete ph ysical examination will be performed at the time points described in Table 1 and 
Table 2 by a qualified licensed ph ysician, ph ysician‚Äôs assistant, or nurse practitioner.
The phy sical examination will include a review of the following bod y systems:
ÔÇ∑General appearance
ÔÇ∑Skin
ÔÇ∑Head, ey es, ears, nose, and throat
ÔÇ∑Spine/neck/thy roid
ÔÇ∑Musculoskeletal
ÔÇ∑Respiratory
ÔÇ∑Cardiovascular
ÔÇ∑Neurological
ÔÇ∑Abdomen (including liver and kidney s)
Shire CONFIDENTIAL Page 38
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Clinically  significant abnormalities identified at the screening visit will be documented in the 
subject‚Äôs source documents and on the medical history  CRF. Changes after the screening visit 
will be captured as AEs on the AE CRF page, as deemed b y the investigator.
7.2.2.3 Adverse Event Collection
At each stud y visit, subjects will be question ed in a general way  to ascertain if AEs have 
occurred since the previous visit (eg, ‚ÄúHave you had an y health problems since your last visit?‚Äù). 
Adverse events are collected from the time informed consent is signed. (Please refer to Section 8, 
Adverse and S erious Adverse Events Assessment.)
7.2.2.4 Vital Signs
Blood Pressure and Pulse Rate
Blood pressure and pulse rate will be measured at times specifi
ed in Table 1 and Table 2 of this 
protocol. Additional BPand pulse rate measurements may  be performed, as determine d by the 
investigator, in order to ensure appropriate monitoring of subject safety and accurate recording of 
vital sign measurements. Any changes from baseline which are deemed clinically  significant by  
the investigator are to be recorded as an AE.
The sam e method for obtaining BPmeasurement (auscultatory  or oscillometric) should be used 
throughout the stud y for all subjects (and documented). In addition, the conditions of vital sign 
measurements should be controlled and as consistent as possible during th e study , in order to 
minimize external variability  of the readings. It is advised that measurements be collected at a 
comfortable room temperature with little to no background noise, using the same (appropriatel y 
sized) cuff placed at the same location of the same arm during the study . The bladder deflation 
rate should be deflated (calibrated for oscillometric method or manuall y by auscultatory  method) 
at a rate of 2 -3 mmHg/s (and the first and last audible sounds recorded as s ystolic and diastolic 
pressure ) after at least 5 minutes of rest in the assumed position.
The cuff should have a bladder length that is 80% and a width that is at least 40% of arm 
circumference (a length -to-width ratio of 2:1). 
The subject should be asked to remove all clothing that c overs the location of cuff placement. 
The subject should not have exercised or consumed caffeine, alcohol, or nicotine within the time 
frame(s) outlined in the Restrictions Section 4.3. The subject should be instructed to relax as 
much as possible for at l east 5 minutes prior to collection. The subject should remain q
uiet 
during this time and through the measurement.
The subject should be l ying comfortably, with the legs uncrossed. The arm should be supported 
with a pillow, such that the middle of the cuff on the upper arm is at the level of the right atrium 
(approximately  halfway  between the bed and the level of the sternum) .
Shire CONFIDENTIAL Page 40
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
7.2.2.5 Clinical Laboratory Evaluations
All clinical laboratory  assay s will be performed according to the laboratory ‚Äôs normal procedures. 
Reference ranges are to be supplied by  the laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out-of-range pathological changes. The investigator 
should assess out -
of-range clinical laboratory  values for clinical significance, indicating if t he 
value(s) is/are not clinically  significant or clinically  significant. Abnormal clinical laboratory  
values, which are unexpected or not explained by  the subject‚Äôs clinical condition, may , at the 
discretion of the investigator or sponsor, be repeated as s oon as possible until confirmed, 
explained, or resolved.
The following clinical laboratory  assessments will be performed: 
Biochemistry
Blood samples (8.5 mL) for serum biochemistry  will be collected into a red top gel separator 
tube at the time points des cribed in Table 1 and Table 2 . The following parameters will be 
assessed: 
Sodium Phosphorus ÔÅ¢-hCG b
Potassium Total protein FSH b
Glucose Total CO 2(Bicarbonate)
Blood urea nitrogen Albumin
Creatinine Aspartate transaminase 
Calcium Alanine trans aminase 
Chloride Gamma glutamy l transferase 
Thyroid stimulating hormone (TSH)aAlkaline phosphatase 
Thyroxine (T4 total) aTotal bilirubin 
Triiodothy ronine (T3) aUric acid
aCollected at Screening only.
bFemales only (Please refer to Table 1and Table 2for collection timepoints). 
Hematology
Blood samples (4mL) for hematology  will be collected into a K 2-EDTA tube at the time points 
described in Table 1 and Table 2. 
Shire CONFIDENTIAL Page 41
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Thefollowing parameters willbeassessed:
Hemoglobin Total neutrophils (absolute)
Hematocrit Eosinophils (absolute)
Red blood cells Monocy tes (absolute)
Platelet count Basophils (absolute)
White blood cell count; total and differential Lym phocy tes (absolute)
Coagulation
Blood samples (2.7mL) for coagulation will be collected into a sodium citrate tube at the time 
points outlined in Table 1 and Table 2. The following parameters will be assessed:
PT PTT INR
Urinalysis
A urine sample for urinaly sis will be collected at the time points described in Table 1 and Table 
2. The f ollowing parameters will be assessed:
pH Blood Nitrites
Glucose Ketones Leukocy te esterase
Protein Bilirubin Specific gravit y
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinaly sis. At a minimum the microsco pic examination will consist of red blood cells, white 
blood cells, casts, and bacteria. 
7.2.2.6 Pregnancy Test 
A serum Œ≤
-HCG pregnancy  test is to be performed on all females at the timepoints outlined in 
Table 1 and Table 2; if pregnancy  is suspected; or on withdrawal of the subject from the study .
7.2.2.7
Drug and Alcohol Screen 
A urine screen for drugs of abuse and alcohol (bre ath test) will be performed at the time points 
described in Table 1 and Table 2. Additional drug and alcohol screens may  be performed at the 
investigator‚Äôs discretion.
Urine samples are to be tested for amphetamines, barbiturates, benzodiazepines, cannabin oids, 
cocaine, methadone, opiate metabolite, and phencyclidine.
Results of urine drug and alcohol (breath test) screens will be reviewed and verified b y the stud y 
monitor, but will not be collected in the CRF database.
Shire CONFIDENTIAL Page 42
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Any positive result for drugs of abus e or alcohol at screening or on Day  -1 will exclude the 
subject from further participation in the study .
If any drug s of abuse or alcohol results are positive at an
y timepoint after the subject has been 
dosed, the principal investigator must contact the Sponsor ‚ÄôsMedical Monitor to discuss and 
review the circumstances, and determine whether the subject may  continue in the study .Details 
of the discussion and decision taken must be properly recorded in the subject‚Äôs source 
documents.
7.2.2.8 Serology Screen 
At the screening visit, a blood sample of approximately 8.5mL will be drawn into a serum 
separator tube to test for the presence of HIV, HBsAg, and HCV antibod y.
The test results must be confirmed negative prior to enrollment in the study. If a test result is 
positive, the subject will be excluded from entering the stud y. Results of the virology  screen will 
be reviewed and verified by  the study  monitor, but will not be collected in the CRF database.
7.2.2.9 Electrocardiogram 
Twelve -
lead ECGs will be performed at the times specified in Table 1 and Table 2. Triplicate 
ECGs will be performed at Screening and Day  -1 only . Thereafter, single ECG recordings will 
be performed at all subsequent timepoints. All ECGs will be performed using the equipment 
supplied by  the CRC. 
The following parameters will be recorded on the appropriate CRF page: heart rate, PR, RR, 
QRS, and QT intervals. The QTcB and QTcF will be derived from the data in the database. The 
investigator‚Äôs assessment of the ECG tracing as normal or abnormal must be do cumented, and if 
abnormal, his/her determination of whether the abnormality  is clinicall y significant or not will be 
documented on the tracing and recorded in the CRF.
The subject should be asked to remove all clothing that covers the location of lead plac ement. 
The subject should not have exercised or consumed caffeine, alcohol, or nicotine within the 
timeframe as described in the Restrictions Section 4.3. The subject must be resting in the supine 
position for at least 5 minutes prior to collecting the ECG
.
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads are placed in the 
same positions each time in order to achieve precise ECG recordings. 
Triplicate ECG Recordings ‚Äì(Screening and Day -1)
Triplicate recording, including a 10 -second rhy thm strip, will be obtained approximately  
2-4minutes apart at the initial Screening Visit and at check in to the CRC on Day  -1. Each ECG 
parameter obtained wit h the 3 assessments will be recorded in the CRF. The average of the 
triplicate ECG measurements collected at each nominal time point will be used for analysis. The 
3 recordings should be immediately
 assessed as valid recordings and if not valid, they  shoul d be 
repeated in order to obtain a total of 3 valid recordings. Invalid recordings will not be entered in 
the CRF.
Shire CONFIDENTIAL Page 43
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Single ECG Recordings ‚Äì (Day 1 through Day 112)
One complete recording, including a 10 -second rhy thm strip, should be taken at all time point s 
except at the initial Screening Visit and at check in to the CRC on Day  -1. It should be 
immediately  assessed as a valid recoding and if not valid, it should be repeated. Invalid 
recordings will not be entered in the CRF.
When a single ECG recording is p erformed at each time point, the ECG collected predose on 
Day 1 will serve as the subject‚Äôs baseline ECG.
To ensure safet y of the subjects, a qualified individual at the investigator site will make 
comparisons to baseline measurements.
If the QTcF interval (calculated onli
ne on site) is increased b y >45 msec from the baseline or an 
absolute QTcF value is >500msec for an y scheduled ECG, then 2 additional ECGs will be 
collected, approximately  2-4 minutes apart, to confirm the original measurement. If either of the 
QTcF values from these repeated ECGs remain s above the threshold value (>4 msec from the 
baseline; or is >500msec), then a single ECG must be repeated at least hourly until QTcF values 
from 2 successive ECGs fall below the threshold value that tri ggered the repeat measurement.
If QTcF values remain above 500msec (or >45msec from the baseline) for >4 hours (or sooner at 
the discretion of the investigator) or QTcF intervals get progressivel y longer, the subject should 
undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF intervals do 
not return to <500msec (or to <45msec above the baseline) after 8 hours of monitoring (or 
sooner at the discretion of the investigator).
If a machine -read QTcF/QTcB value is prolonged, as defined above , repeat measurements may  
not be necessary  if a qualified phy sician‚Äôs interpretation determines that the QTcF/QTcB values 
are in the acceptable range .
7.2.3 Pharmacokinetic Procedures
The name and address of the bioanal ytical laboratory  for this study  will be ma intained in the 
investigator‚Äôs files at the study  site and in the Trial Master File at the sponsor.
Actual pharmacokinetic blood sample collection times versus time of dosing will be monitored. 
The sponsor‚Äôs expectation is that the investigator will ensure that every  effort is made to collect 
all pharmacokinetic blood samples at the precise protocol scheduled time. Pharmacokinetic 
blood collection must not deviate from the nominal collection time set forth in the protocol by 
more than ÔÇ± 5 minutes from sample s drawn within 4 hours postdose or b y more than ÔÇ±15 minutes 
for samples drawn bey ond 4 hours postdose. Samples drawn outside these parameters will be 
considered a protocol deviation. 
7.2.3.1 Pharmacokinetic Sample Collection and Handling Procedures
Pharmacokineti c blood samples will be collected at the time specified in Table 1 and Table 2 to 
measure plasma concentrations of lanadelumab. A full description of the PK blood collection, 
handling, storage ,and shipping can be found in the provided laboratory  manual.
Shire CONFIDENTIAL Page 44
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Plasma sample tubes for bioanaly sis must be freezer -safe and identified with freezer -safe labels 
provided b y the CRC. The labels will contain the following information:
ÔÇ∑Study  number
ÔÇ∑Subject identifier
ÔÇ∑Nominal day
ÔÇ∑Nominal time
ÔÇ∑Matrix identifier (plasma)
ÔÇ∑Split (primary  or backup)
7.2.3.2 Shipment of Plasma Pharmacokinetic Samples
Instructions for shipment of all PK samples (along with the corresponding documentation) can 
be found in the laboratory  manual provided under a separate cover.
Pharmacokinetic samples will b e stored nominally at -70(¬± 10)¬∞C prior to and after anal ysis at the 
CRO until further directions are authorized b y Shire.
7.2.3.3 Plasma Drug Assay Methodology
Plasma sample anal ysis will be performed according to Shire Standard Operating Procedure 
BC-104 (current version) . Under circumstances where this Shire Standard Operating Procedure 
does not apply , relevant TGA Sciences (the bioanaly tical lab) Operating Procedures will be 
followed
.
Plasma concentrations will be measured using the most current validated bioana lytical method. 
In addition, selected plasma samples may  be used to investigate incurred sample reproducibility  
(full details will be described in the bioanal ytical study  plan). The presence of other metabolites 
or artifacts may  be monitored or quantified as appropriate. Raw data will be stored in the archive 
of the designated bioanaly tical contract laboratory. 
7.2.4 Pharmacodynamic Assessments
The names and addresses of the bioanal ytical laboratories for this stud y will be maintained in the 
investigator‚Äôs files at the site and in the Trial Master File at the sponsor.
Actual PD blood sample collection times versus time of dosing will be monitored. The sponsor‚Äôs 
expectation is that the investigator will ensure that every  effort is made to collect all PD blood 
samples at the precise protocol scheduled time. Pharmacod ynamic blood collection must not 
deviate from the nominal collection time set forth in the protocol by  more than ¬±5 minutes from 
samples drawn within 4 hours postdose or b y more than ¬±15 minutes for samp les drawn at 
4 hours post dose and beyond while in the CRC. For PD samples drawn during the out- patient 
visits refer to Table 2 for time point parameters. Samples drawn outside the parameters set forth 
in the protocol will be considered a protocol deviatio n.
Shire CONFIDENTIAL Page 45
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
7.2.4.1 Pharmacodynamic Sample Collection and Handling Procedures
Pharmacod ynamic blood samples will be collected at the time specified in Table 1 and Table 2 to 
measure plasma concentrations of kallikrein activity  and cHMWK. A full description of the PD 
blood collection, handling, storage and shipping can be found in the provided laboratory manual.
Plasma sample tubes for bioanaly sis must be freezer -safe and identified with freezer -safe labels 
provided b y the CRC. The labels will contain the following informati on:
ÔÇ∑Study  number
ÔÇ∑Subject identifier
ÔÇ∑Nominal day
ÔÇ∑Nominal time
ÔÇ∑Matrix identifier ( plasma )
ÔÇ∑Analy te (kallikrein activity  or cHMWK)
ÔÇ∑Split (primary  or backup)
7.2.4.2 Shipment of Plasma Pharmacodynamic Samples
Instructions for shipment of all PD samples (along with the corresponding documentation) can 
be found in the laboratory  manual provided under a separate cover.
Pharmacod ynamic samples will be stored nominally at -
70(¬±10)¬∞C prior to and after anal ysis at 
the CRO until further direction is authorized by  Shire.
7.2.4.3 Plasma Pharmacodynamic Assay Methodology
Plasma levels of kallikrein activity  and cHMWK will be measured using the most current 
validated bioanal ytical methods. The presence of other metabolites or artifacts may  be monitored 
or quantified as appropriate. Raw dat a will be stored in the archive of the designated 
bioanaly tical contract laboratory .
7.2.5 Immunogenicity Testing for Anti -Drug Antibodies
The name and address of the bioanal ytical laboratory  conducting ADA immunogenicit y testing 
for this study  will be maintaine d in the investigator‚Äôs files at the stud y site and in the Trial 
Master File at the sponsor.
Actual 
ADA blood sample collection times versus time of dosing will be monitored. The 
sponsor‚Äôs expectation is that the investigator will ensure that every  effort is made to collect all 
anti-drug blood samples as the precise protocol scheduled time. Anti- drug antibody  blood 
collection will be collected on Day  1 prior to dose (within 60 minutes of dose). See Table 2 for a 
detailed schedule of time points. A full desc ription of the ADA blood collection, handling, 
storage and shipping can be found in the provided laboratory  manual.
In the event anti -drug antibodies are detected following anal ysis for a subject, the investigator 
will be notified by the sponsor. It will b e the investigator‚Äôs responsibility  to notify  the subject.
Shire CONFIDENTIAL Page 46
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
7.2.6 Volume of Blood to Be Drawn from Each Subject
Table 3: Volume of Blood to Be Drawn from Each Subject
Assessment Sample Volume (mL)Number of 
SamplesTotal Volum
e (mL)
Pharmacokinetic samplesa5 14 70
Pharm acody namic (cHMWK and 
plasma kallikrein activity ) samples 5 14 70
HBsAg, HIV, HCV 8.5 1 8.5
Safety Biochemistry, FSH 
and ÔÅ¢-hCGa,b,c8.5 12 102
Hem atology 4 12 48
Coagulation
(PT, aPTT, INR)2.7 11 29.7
Anti-Drug Antibody samples 3 5 15
Total mL 343.2
ÔÅ¢-hCG=beta -human chorionic gonadotropin; FSH = follicle stimulating hormone; HBsAg=hepatitis B surface antigen; 
HCV=hepatitis C virus; HIV=human immunodeficiency virus; TSH=thyroid stimulating hormone; T3=trii odothyronine; 
T4= thyroxine
aIf a catheter is used for any blood draw or series of blood draws then the first 1mL is to be discarded. The 1mL discard has 
been taken into account in the table above and the total blood volume required for this study.
bÔÅ¢-hCG and FSH testing for females only.
cTSH, T3 and T4 will be included in the biochemistry panel, and collected at Screening only.
During this stud y, it is expected that approximately 343.2mL of blood will be drawn from all 
subjects, regardless of sex.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  the manufacturer or laboratory  
for an individual assessment; however, the total volume drawn over the co urse of the study  
should be approximately  343.2mL . When more than 1 blood assessment isto be done at the time 
point/period, if they  require the same type of tube, the assessments may  be combined.
8 ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is an y untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily  have a causal relationship with this 
treatm ent. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigat ional) product (ICH 
Guidance E2A 1995).
Shire CONFIDENTIAL Page 47
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.2.3 . This includes events occurring during the screening phase of the 
study , regardless of w hether or not investigational product is administered. Where possible, a 
diagnosis rather than a list of sy mptoms should be recorded. If a diagnosis has not been made, 
then each s ymptom should be listed individually . All AEs should be captured on the appro priate 
AE pages in the CRF and in source documents. In addition to untoward AEs, unexpected 
benefits outside the investigational product indication should also be captured on the AE CRF.
All AEs must be followed to closure (the subject‚Äôs health has returne d to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  furthe r improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The severit y of AEs must be recorded dur ing the course of the event including the start and stop 
dates for each change in severity. An event that changes in severity should be captured as a new 
event. Worsening of pre -treatment events, after initiation of investigational product, must be 
recorde d as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of se vere dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate CRF).
The medical assessment of severit y is determined by using the following definitions:
Mild: A type of AE that is usually  transient and may  require only  minimal treatmen t or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  livin g, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic interven tion.
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the e vent may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as ‚Äúnot 
related‚Äù. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspectin g 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered ‚Äúrelated‚Äù. The causality  assessment must be 
documented in the source document.
Shire CONFIDENTIAL Page 48
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the 
investigational product is compelling and/or follows a known or suspected response 
pattern to that product, and the event cannot be explained by the subject‚Äôs medical 
condition, other therapies, or accident.
Not RelatedThe event can be readily explained by other factors such as the subject‚Äôs underlying 
medical condition, concomitant therapy, or accident and no plausible temporal or 
biologic relationship exists between the investigational product and the event.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the stud y on the CRF. Outcomes are 
as follows:
ÔÇ∑Fatal
ÔÇ∑Not Recovered/Not Resolved
ÔÇ∑Recovered/Resolved
ÔÇ∑Recovered/Resolved With Sequelae
ÔÇ∑Recovering/Resolving
ÔÇ∑Unknown
8.1.4 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory , vital sign, or ECG assessment can represent an AE 
if the change is clinically relevant or if, during treatment with the investigational product, a shift 
of a parameter is observed from a normal value to an abnormal value, or a further worsening of 
an alread y abnormal value. When evaluating such changes, the extent of deviation from the 
refer ence range, the duration until return to the reference range, either while continuing treatment 
or after the end of treatment with the investigational product, and the range of variation of the 
respective parameter within its reference range, must be taken into consideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory , vital sign, or ECG 
values which were not present at the pretreatment value observed closest to the start of study  
treatment, further investigations should b e performed until the values return to within the 
reference range or until a plausible explanation (eg, concomitant disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subje ct, whether a change in a clinical laboratory , vital sign, or ECG parameter is clinicall y 
significant and therefore represents an AE.
Shire CONFIDENTIAL Page 49
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
8.1.5 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period s tated in Section 7.1.2.3.
Any report of pregnancy  for any  female study  participant or the partner of a male study  
participant must be reported within 24 hours to the Shire Global Drug Safety  Department using 
the Shire Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -
up 
reports) must also be sent to the CRO/Shire medical monitor using the details specified in the 
emergency  contact informatio n section of the protocol. The pregnant female study  participant 
must be withdrawn from the study .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator t o obtain this information within 
30 calendar day s after the initial notification and approximately  30 calendar day s post partum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be repo rted using the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by  the Protocol Form. Note: An elective abortion is not 
considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious crit eria, 
it must be reported as an SAE using the Shire Clinical Study  Serious Adverse Event and 
Non-serious AEs Required by  the Protocol Form as well as the Shire Investigational and 
Marketed Products Pregnancy  Report Form. The test date of the first positive serum/urine ÔÅ¢ -hCG 
test or ultrasound result will determine the pregnancy  onset date.
8.1.6 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporti ng procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE. 
The categories bel ow are not mutually  exclusive; the event can meet more than 1 category .
ÔÇ∑Abuse ‚Äì
Persistent or sporadic intentional intake of investigational product when used for a 
non-medical purpose (eg, to alter one‚Äôs state of consciousness or get high) in a manner tha t 
may be detrimental to the individual and/or society
ÔÇ∑Misuse ‚ÄìIntentional use of investigational product other than as directed or indicated at any  
dose (Note: this includes a situation where the investigational product is not used as directed 
at the dose prescribed b y the protocol)
ÔÇ∑Overdose ‚ÄìIntentional or unintentional intake of a dose of investigational product higher 
than the protocol -prescribed dose
Shire CONFIDENTIAL Page 50
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
ÔÇ∑Medication Error ‚ÄìAn error made in prescribing, dispensing, administration, and/or use of 
an investigat ional product. For studies, medication errors are reportable to the sponsor only  
as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/repo rted for all products under investigation.
The administration and/or use of an expired investigational product should be considered as a 
reportable medication error.
The administration of investigational product to an eligible volunteer following a tempera ture 
excursion as outlined in the pharmacy  manual, without assessment of the excursion and 
permission of the sponsor to proceed is deemed a medication error.
It is not expected that overdose would occur in this study .
The investigational product used in 
this study  is supplied in 1strength (300 mg) and is administered once per volunteer b y a trained 
and responsible staff member at the stud y site with sponsor oversight. 
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safet y information for this study  is the lanadelumab Investigator‚Äôs Brochure 
which the sponsor has provided under separate cover to all investigators.
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by  the investigator to the Shire Globa l
Drug Safet y Department and the CRO/Shire medical monitor within 24 hours of the first 
awareness of the event. Note: The 24 -hour reporting requirement for SAEs does not apply  to 
reports of abuse, misuse, overdose, or medication errors (see Section 8.1.6) unless they  result in 
an SAE.
The investigator must complete, sign, and date the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by  the Protocol Form and verify  the accuracy  of the information 
recorded on the form with the correspon ding source documents (Note: Source documents are not 
to be sent unless requested) and fax or e -mail the form to the Shire Global Drug Safet y 
Department. A cop y of the Shire Clinical Study  Serious Adverse Event and Non
-serious AEs 
Required b y the Protocol Form (and an y applicable follow -up reports) must also be sent to the 
CRO/Shire medical monitor using the details specified in the emergency  contact information 
section of the protocol.
Shire CONFIDENTIAL Page 51
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
8.2.3 Serious Adverse Event Definition
AnSAE is any  untoward medical occurre nce (whether considered to be related to investigational 
product or not) that at any dose:
ÔÇ∑Results in death
ÔÇ∑Is life -threatening. Note: The term ‚Äúlife-threatening‚Äù in the definition of ‚Äúserious‚Äù refers to an 
event in which the subject was at risk of death a t the time of the event; it does not refer to an 
event which h ypothetically might have caused death if it was more severe.
ÔÇ∑Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations that are the result of electiv e or previously  scheduled surgery  for 
pre-existing conditions and have not worsened after initiation of treatment should not be 
classified as SAEs. For example, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE ; however, complication(s) resulting from a 
hospitalization for an elective or previousl y scheduled surgery  that meet(s) serious criteria 
must be reported as SAE(s).
ÔÇ∑Results in persistent or significant disability /incapacity
ÔÇ∑Is a congenital abnormality /birth defect
ÔÇ∑Is an important medical event. Note: I mportant medical events that may  not result in death, 
be life -threatening, or require hospitalization may  be considered an SAE when, based upon 
appropriate medical judgment, they  may  jeopardize the subject an d may  require medical or 
surgical intervention to prevent 1 of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency  
room or at home; blood dyscrasias or convulsi ons that do not result in inpatient 
hospitalization; or the development of drug dependency  or drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow -up period stated in Section 7.1.2.3 and must be 
reported to the Shire Global Drug Safet y Department 
andthe CRO/Shire medical monitor within 
24 hours of the first awareness of the event.
In addition, any  SAE(s) considered ‚Äúrelated‚Äù to the investigational product and discovered by  the 
investigator at an y interval after the study has completed must be reported to the Shire Global
Drug Safet y Department within 24 hours of the first awareness of the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
event is considered chronic. I nthe case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectivel y.
Shire CONFIDENTIAL Page 52
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
In addition, any  signs or sy mptoms experienced by  the subject after signing the informed consent 
form, or leading up to t he onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subject‚Äôs death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject‚Äôs death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject‚Äôs death or any  ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be reco rded as ‚Äúdose not 
changed‚Äù or ‚Äúnot applicable‚Äù (if the subject never received investigational product). The 
investigational product action of withdrawn should not be selected solel y as a result of the 
subject‚Äôs death.
8.2.7 Regulatory Agency, Institutional Revie w Board, Ethics Committee, and Site 
Reporting
The sponsor is responsible for notify ing the relevant regulatory  authorities/US Central 
Institutional Review Board (IRB) of related, unexpected SAEs.
In addition the sponsor is responsible for notify ing active sites of all related, unexpected SAEs 
occurring during all interventional studies across the SHP643 program. 
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
9 DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators‚Äô authorized site personnel must enter the information required by  the protocol 
on the CRF. A study  monitor will visit each site in accordance with the monitori ng plan and 
review the CRF data against the source data for completeness and accuracy. Discrepancies 
between source data and data entered on the CRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by  authorized site 
personnel. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator‚Äôs meeting. Once a subject is enrolled, it is expected that site personnel 
will complete the CRF entry  within approximately  3 business day s of the subject‚Äôs visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO‚Äôs data management plan. 
Quality  control and data validation procedures are applied to ensure t he validity  and accuracy  of 
the clinical database.
Shire CONFIDENTIAL Page 53
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only  authorized personnel will make corrections to 
the clinical database, and all corrections are to be documented in an auditable manner.
9.3 Data Handling Considerations 
All analy ses/summaries will be based on observed data, with no imputation for missing data, 
unless otherwise specified in the study  Statistical Analy sis Plan (SAP).
9.4 Statistical Analysis Process
No statistical hy pothesis testing is planned. Analysis details will be provided in the SAP.
Study  data will be anal yzed by the sponsor or its agent (CRO) .To preserve the integrit y of the 
statistical analy sis and study  conclusions, t he SAP will be finalized prior to study  database lock. 
The SAP will provide the statistical methods and definitions for the anal ysis of the 
pharm acokinetic, pharmacody namic, and safet y data, as well as describe the approaches to be 
taken for summarizing other study  information such as subject disposition, demographics and 
baseline characteristics, investigational product exposure, and prior and con comitant 
medications. The SAP will also include a description of how missing, unused and spurious data 
will be addressed.
All statistical analy ses will be performed using SASÔÉí(SAS I nstitute, Cary , NC 27513). 
Descriptive anal ysis will be performed to eval uate all primary , secondary  and exploratory  
endpoints, and the following, including the definition below, will apply :
ÔÇ∑Continuous endpoints (eg, change in parameter) will be summarized, display ing: number of 
subjects (n), mean, standard deviation (SD), medi an, minimum and maximum value. As 
appropriate, raw (actual) values, changes from baseline, and percent changes from baseline 
will be summarized overall and at each scheduled timepoint. Baseline is defined as the last 
non-missing value prior to dosing with investigational product (lanadelumab). Additional 
summary  statistics will be provided for pharmacokinetic and pharmacody namics endpoints 
and are indicated in Sections 9.8.1 and 9.8.2. 
ÔÇ∑Categorical endpoints (eg, presence or absence of an outcome measure) will be summarized, 
display ing counts and percentages. Summaries will include, where applicable: number and 
percentage of subjects with an outcome measure and shift tables (categorical change from 
baseline).Summaries will be presented by  racial/ethnic group (Japanese vs. non -Hispanic 
Caucasians), and, if appropriate, b y timepoint. Matching of non -Hispanic Caucasian subjects 
to Japanese subjects, according to the stud y design, is intended to ensure that the ethnic/racial 
groups are comparable at baseline with
respect to the matching factors ( sex, age, and bod y 
mass index). All subject volunteers will receive a single SC dose 300mg of lanadelumab in 
the abdomen on 
Day 1.
Shire CONFIDENTIAL Page 54
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
All data, including derived data, will be presented in subject data listings and all listings will 
include subject‚Äôs sex, age, race/ethnicity , and body mass index.
9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee
No interim anal ysis, adaptive design, or Data Monitoring Committee (DMC )is planned.
9.6 Sample Size Calculation and Power Considerations
The planned sample size for this study  is 32 subjects: 16 subjects of Japanese descent and 
16matched non -Hispanic Caucasian subjects. 
Assuming a 25% dropout rate, the sample size ensures approximately 24 subjects (12 Japanese 
and 12 matched Caucasians) complete the study , and 24 subjects are evaluable for 
pharmacokinetic anal ysis purposes. The sample size is considered adequate for the primary  and 
secondary  objectives of the study  and therefore adequate for providing reliable estimates of 
pharmacokinetic parameters. 
The sample size was based on clinical judgment and precedent pharmacokinetic studies of 
similar design and similar subject population and not on statistical considerations such as study  
power. Subjects who prematurely discontinued the study , whether subjects are part of matched 
pairs or are not yet matched, may be replaced at the discretion of the stud y sponsor to ensure 
there are approximately  12 evaluable subjects in each racial/ethnic group for pharmacokinetic 
analysis purposes.
9.7 Analysis Populations/ Analysis Sets
Safety , PK and PD anal yses will be based on the following subject populations (anal ysis sets), as 
defined:
ÔÇ∑Safety  population (Safet y Analysis Set): All subjects who received at least 1 dose of 
lanadelumab ( study  drug).
ÔÇ∑Pharmacokinetic population (PK Set): All subjects who received at least 1 dose of 
lanadelumab and have at least 1 evaluable postdose PK concentration value.
ÔÇ∑Pharmacod ynamic population (PD Anal ysis Set): All subjects who received at least 1 d ose of 
lanadelumab and have at least 1 evaluable postdose PD concentration value. 
ÔÇ∑Enrolled Set: All subjects for whom an enrollment number has been assigned.
9.8 Pharmacokinetic and Pharmacodynamic Analyses
9.8.1 Pharmacokinetic Analysis
Pharmacokinetic parameters will be calculated using plasma concentration -time data by  
non-compartmental methods and all calculations will be based on actual sampling times. 
Shire CONFIDENTIAL Page 55
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Baseline is defined as the Day  1 predose concentration. Pharmacokinetic parameters will be 
estimated by  noncom partmental anal ysis and will include, but not be limited to, the following:
ÔÇ∑Cmax: Maximum observed plasma drug concentration
ÔÇ∑tmax: Time to reach C maxin plasma
ÔÇ∑AUC 0-last: Area under the concentration -time curve from time zero to the last quantifiable 
conce ntration in plasma
ÔÇ∑AUC 0-‚àû: Area under the concentration -time curve from time zero extrapolated to infinity
ÔÇ∑ ÔÅ¨ z:Terminal elimination rate constant
ÔÇ∑t¬Ω:Terminal half -life
ÔÇ∑CL/F: Apparent clearance
ÔÇ∑Vdz/F: Apparent volume of distribution
Body weight -adjusted AUClast, Cmax, CL /F, and Vdz/F will be estimated as well.
9.8.1.1 Statistical Analysis of Pharmacokinetic Parameters
Pharmacokinetic parameters of lanadelumab and plasma concentrations at each nominal 
sampling time will be provided in subject data listing(s) and summarized using descript ive 
statistics (number of subjects, arithmetic mean, SD, coefficient of variation [CV%], median, 
minimum, maximum, geometric mean, and %CV of geometric mean), presented by  racial/ethnic 
group (Japanese vs non- Hispanic, Caucasian). In addition, 95% confiden ce intervals for key  PK
parameters will be provided as appropriate, as well as graphs of individual and mean (¬± SD) 
concentration -time profiles plasma lanadelumab and graph(s) of observed and weight -adjusted 
PK parameters (y -axis) versus body  weight (x -axis). 
All plasma concentration values below the lower limit of quantification (LLOQ) will be set to 
zero when calculating summary statistics. For the calculation of PK parameters, all plasma 
concentrations that are LLOQ prior to the first measurable concent ration will be set to zero. The 
LLOQ values that are between measurable concentrations will be set to missing. The LLOQ 
values following the last quantifiable timepoints will be set to missing. No concentration 
estimates will be imputed for missing sample values. Any  sample with a missing value will be 
treated as if the sample had not been scheduled for collection and will be ignored when 
calculating mean concentrations or PK parameters.
Pharmacokinetic anal ysis will be based on the Pharmacokinetic populati on.
9.8.2 Pharmacodynamic Analysis
Pharmacod ynamic assessment is an exploratory  objective of the study . Individual subject plasma 
kallikrein activity  and plasma cHMWK with and without baseline correction will be provided in 
subject data listings and summarized u sing descriptive statistics (number of subjects, arithmetic 
mean, SD, CV%, median, minimum, maximum, geometric mean, and %CV of geometric mean),
presented by racial/ethnic group (Japanese vs. non-Hispanic, Caucasian). 
Shire CONFIDENTIAL Page 56
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Inaddition, 95% confidence intervals will be provided as appropriate. Graphs of individual and 
mean (¬±SD) activity -time profiles will be generated.
Pharmacod ynamic anal ysis will be based on the Pharmacod ynamic population.
9.8.3 Pharmacokinetic and Pharmacodynamic Analysis
Not applicable.
9.9 Safety Analyses
Safety  endpoints are defined in the Sy nopsis section. Descriptive anal ysis, as described in 
Section 9.4 will be performed to evaluate all safet y endpoints.
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities. The 
numbe r of events, incidence, and percentage of treatment
-emergent adverse events (TEAEs) will 
be calculated overall, by  system organ class, by  preferred term, and by  treatment group.
Treatment -emergent adverse events will be further summarized by severit y and r elationship to 
investigational product. Adverse events related to investigational product, AEs leading to 
withdrawal, SAEs, and deaths will be similarly  summarized/ listed.
Only  TEAEs will be analy zed. All AEs ( TEAEs and non -TEAEs ) will be provided in the AE 
subject listing. All safet y data, including derived data, will be presented in subject data listings, 
and all listings will include subject‚Äôs sex, age, race/ethnicity , and body  mass index.
Clinical laboratory  tests, vital signs, and ECG findings will be summarized, as appropriate, b y 
racial/ethnic group (Japanese vs. non- Hispanic ,Caucasian) and visit. Potentially  clinicall y 
important findings will also be summarized or listed in subject data listing.
Safety  anal ysis will be based on the Safet y populatio n.
Definition
Treatment -emergent adverse events (TEAEs) : TEAEs are AEs with onset at the time of or 
following the first exposure to study drug, or medical conditions present prior to the start of 
study  drug but increasing in severity  or relationship at the time of or following the start of 
treatment, up to the last follow -up visit.
9.10 Other Analyses
No other anal yses are planned.
9.10.1 Exploratory Analysis
Pharmacod ynamic anal ysis is the exploratory  analy sis. Refer to Section 9.8.2 for anal ysis.
Shire CONFIDENTIAL Page 57
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
10 SPONSOR‚ÄôS AND INVEST IGATOR‚ÄôS RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements.
The name and address of each third -party vendor (eg, CRO) used in t his study  will be maintained 
in the investigator‚Äôs and sponsor‚Äôs files, as appropriate.
10.1 Sponsor‚Äôs Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been deleg ated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are con ducted by  representatives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects‚Äô 
medical records, and CRFs in accordance with current good c linical practice (GCP )and the 
respectiv e local and inter/national government regulations and guidelines. Records and data may  
additionally  be reviewed by  auditors or by  regulatory  authorities.
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the investigator as necessary .
10.1.3 Public Posting of Study Information
The sponsor is responsibl e for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators‚Äô names 
and contact information.
10.1.4 Submission of Summary of Clinical Study Report to Competent Author ities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for non -pediatric studies as per 
guidance. 
Shire CONFIDENTIAL Page 58
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the stud y, or part of the stud y, at any time for an y reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinu ation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
10.2 Investigator‚Äôs Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator‚Äôs responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commit ment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriat ely qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vit ae for investigators and sub -investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject‚Äôs consent, inform them of the subject‚Äôs participation in the study .
Agreement with the final clinical study  report is documented by  the signed and dated signature 
of the principal investigator, in compliance with Directive 2001/83/EC as amended b y Directive 
2003/63/EC and I CH Guidance E3 (1995).
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and an y co-investigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the spons or and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Shire CONFIDENTIAL Page 59
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor, a pplicable CRO, investigator, or, for 
multicenter studies, the coordinating principal investigator, according to national provisions, and 
will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Case report forms are supplied by  the CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no da ta will be recorded directly  onto the 
CRF.
All data sent to the sponsor must be endorsed b y the investigator.
The clinical research associate ( CRA )/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are uncl ear or contradictory , queries are sent for 
corrections or verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject‚Äôs medica l file and original clinical laboratory  reports.
All key  data must be recorded in the subject‚Äôs medical records.
The investigator must permit authorized representatives of the sponsor; the respective national, 
local, or foreign regulatory  authorities; the IRB/EC; and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC, or regulatory  inspectors) may  check the CRF 
entries against the source documents. The consent form includes a statement by  which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or IRB/EC, having access to source data (eg, subject‚Äôs medical file, 
appointment books, original laboratory  reports, X -rays, etc.). 
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, UK Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
Shire CONFIDENTIAL Page 60
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
10.2.3.3 Audit/Inspection
To ensure compliance with r elevant regulations, data generated b y this study must be available 
for inspection upon request by  representatives of, for example, the US FDA (as well as other US 
national and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
10.2.3.4 Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the out come of the study  could be influenced by  the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; an y 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent from all study  
subjects prior to an y study -related procedures including screening assessments. All consent 
documentation must be in accordance with applicable regulations and GCP. Each subject or the 
subject‚Äôs legall y authorized representative, as applicable, is requested to sign and date the subject 
informed consent form or a certified translation if applicable, after the subject has received and 
read (or been read) the written subject information and received an explanation of what the study 
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject‚Äôs rig hts and responsibilities. A copy  of the informed consent documentation (ie, a 
complete set of subject information sheets and fully executed signature pages) must be given to 
the subject or the subject‚Äôs legally  authorized representative, as applicable. Thi
s document may  
require translation into the local language. Signed consent forms must remain in each subject‚Äôs 
study  file and must be available for verification at any  time.
The principal investigator provides the sponsor with a cop y of the consent form th at was 
reviewed b y the IRB/EC and received their favorable opinion/approval. A copy  of the IRB/EC‚Äôs 
written favorable opinion/approval of these documents must be provided to the sponsor prior to 
the start of the stud y unless it is agreed to and documented (abiding b y regulatory guidelines and 
national provisions) prior to study  start that another part y (ie, sponsor or coordinating principal 
investigator) is responsible for this action. Additionally , if the IRB/EC requires modification of 
the sample subject information and consent document provided by  the sponsor, the 
documentation supporting this requirement must be provided to the sponsor.
Shire CONFIDENTIAL Page 61
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator t o submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation.
The applicant for an EC opinion can be the sponsor or investigator for sites within the EU; for 
multicenter studies, the applicant can be the coordinating principal investigator or sponsor, 
according to national provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the clinical trial agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  the sponsor or investigator, or, for multicenter 
studies, it can be done b y the coordinating principal investigator, a ccording to national 
provisions. The investigator must also keep the local IRB/EC informed of any  serious and 
significant AEs.
10.4 Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, where 
applica ble, compl y with HI PAA of 1996. A site that is not a covered entity  as defined by  HIPAA 
must provide documentation of this fact to the sponsor.
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives‚Äô 
reviews their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market lanadelumab; national or local regulatory  authorities; and the I RB/EC which gave 
approval for the study  to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects‚Äô identi ties.
Shire CONFIDENTIAL Page 62
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  results have been assigned to the cor rect subject).
The results of studies ‚Äìcontaining subjects‚Äô unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth ‚Äìwill be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  regulatory or health authorities.
10.5 Study Results/Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether t he outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee. The purpose of 
the publication steering committee is to act as a noncommercial bod y that advises or decides on 
dissemination of scientific study  data in accordance with the scope of this policy .
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review , with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor‚Äôs proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  the 
publisher and cop yright law, the principal investigator will own (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the spons or a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term ‚Äúpublication‚Äù refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  the sponsor that is necessary  to 
include in an y publication of study results, or necessary for other sch olars to verify  such study  
results. Notwithstanding the foregoing, no publication that incorporates the sponsor‚Äôs 
confidential information shall be submitted for publication without the sponsor‚Äôs prior written 
agreement to publish, and shall be given to th e sponsor for review at least 60 day s prior to 
submission for publication. If requested in writing by  Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 day s to 
allow for filing of a p atent application.
Shire CONFIDENTIAL Page 63
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
If the stud y is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor‚Äôs presentation of a joint, multicenter publication 
of the compiled and analy zed study  results. If such a multicenter publication is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study  at all sites, or after the sponsor confirms there shall be no multice nter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
(ICMJE) current standards. Participation as an investigator does not confer an y rights to 
authorship of publications.
Shire CONFIDENTIAL Page 64
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
11 REFERENCES
Bygum, A. 2009. Hereditary  angio-oedema in Denmark: a nationwide survey . The British 
journal of dermatology, 161, 1153-8.
Chiba, K., Yoshitsugu, H ., Ky osaka, Y., Iida, S., Yoney ama, K., Tanigawa, T., Fukushima, T. & 
Hiraoka, M. 2014. A comprehensive review of the pharmacokinetics of approved 
therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed? 
Journal Of Clinical Pharmacology, 54, 483-494.
Goring, H. D., Bork, K., Spath, P. J., Bauer, R., Ziemer, A., Hintner, H. & Wuthrich, B. 1998. 
Hereditary  angioedema in the German
-speaking region. Hautarzt, 49, 114-22.
Lei, W. T., Shyur, S. D., Huang, L. H.,Kao, Y. 
H. & Lo, C. Y. 2011. Type I hereditary 
angioedema in Taiwan --clinical, biological features and genetic study. Asian Pac J 
Allergy Immunol, 29, 327 -31.
Morrison, M., Palermo, G. & Schmitt, C. 2015. Lack of ethnic differences in the 
pharmacokineti cs and pharmacod ynamics of inclacumab in healthy Japanese and 
Caucasian subjects. European Journal of Clinical Pharmacology, 71, 1365-1374.
Nordenfelt, P., Dawson, S., Wahlgren, C. F., Lindfors, A., Mallbris, L. & Bjorkander, J. 2014. 
Quantify ing the burde n of disease and perceived health state in patients with hereditary 
angioedema in Sweden. Allergy Asthma Proc, 35, 185 -
90.
Roche, O., Blanch, A., Caballero, T., Sastre, N., Callejo, D. & Lopez -Trascasa, M. 2005. 
Hereditary  angioedema due to C1 inhibitor deficiency : patient registry  and approach to 
the prevalence in Spain. Ann Allergy Asthma Immunol, 94, 498-503.
Rosario, M., Dirks, N. L., Milch, C., Parikh, A., Bargfrede, M., Wyant, T., Fedyk, E. & Fox, I. 
2017. A Review of the Clinical Pharmacokinetics, Pharmacody namics, and 
Immunogenicit y of Vedolizumab. Clin Pharmacokinet, 56, 1287-1301.
Zuraw, B. L. 2008. Clinical practice. Hereditary  angioedema. N Engl J Med, 359, 1027-36.
Shire CONFIDENTIAL Page 65
Protocol SHP643 -101  
Lanadelumab 27 Nov 2017
12 APPENDICES